<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22772368</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>07</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm.</ArticleTitle>
            <Pagination>
                <MedlinePgn>922-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2349</ELocationID>
            <Abstract>
                <AbstractText>Loeys-Dietz syndrome (LDS) associates with a tissue signature for high transforming growth factor (TGF)-β signaling but is often caused by heterozygous mutations in genes encoding positive effectors of TGF-β signaling, including either subunit of the TGF-β receptor or SMAD3, thereby engendering controversy regarding the mechanism of disease. Here, we report heterozygous mutations or deletions in the gene encoding the TGF-β2 ligand for a phenotype within the LDS spectrum and show upregulation of TGF-β signaling in aortic tissue from affected individuals. Furthermore, haploinsufficient Tgfb2(+/-) mice have aortic root aneurysm and biochemical evidence of increased canonical and noncanonical TGF-β signaling. Mice that harbor both a mutant Marfan syndrome (MFS) allele (Fbn1(C1039G/+)) and Tgfb2 haploinsufficiency show increased TGF-β signaling and phenotypic worsening in association with normalization of TGF-β2 expression and high expression of TGF-β1. Taken together, these data support the hypothesis that compensatory autocrine and/or paracrine events contribute to the pathogenesis of TGF-β-mediated vasculopathies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lindsay</LastName>
                    <ForeName>Mark E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Helen B Taussig Children's Heart Center, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schepers</LastName>
                    <ForeName>Dorien</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bolar</LastName>
                    <ForeName>Nikhita Ajit</ForeName>
                    <Initials>NA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doyle</LastName>
                    <ForeName>Jefferson J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gallo</LastName>
                    <ForeName>Elena</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fert-Bober</LastName>
                    <ForeName>Justyna</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kempers</LastName>
                    <ForeName>Marlies J E</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fishman</LastName>
                    <ForeName>Elliot K</ForeName>
                    <Initials>EK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Yichun</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Myers</LastName>
                    <ForeName>Loretha</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bjeda</LastName>
                    <ForeName>Djahita</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oswald</LastName>
                    <ForeName>Gretchen</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elias</LastName>
                    <ForeName>Abdallah F</ForeName>
                    <Initials>AF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levy</LastName>
                    <ForeName>Howard P</ForeName>
                    <Initials>HP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Anderlid</LastName>
                    <ForeName>Britt-Marie</ForeName>
                    <Initials>BM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Margaret H</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bongers</LastName>
                    <ForeName>Ernie M H F</ForeName>
                    <Initials>EM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Timmermans</LastName>
                    <ForeName>Janneke</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Braverman</LastName>
                    <ForeName>Alan C</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Canham</LastName>
                    <ForeName>Natalie</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mortier</LastName>
                    <ForeName>Geert R</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brunner</LastName>
                    <ForeName>Han G</ForeName>
                    <Initials>HG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Byers</LastName>
                    <ForeName>Peter H</ForeName>
                    <Initials>PH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Eyk</LastName>
                    <ForeName>Jennifer</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Van Laer</LastName>
                    <ForeName>Lut</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dietz</LastName>
                    <ForeName>Harry C</ForeName>
                    <Initials>HC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loeys</LastName>
                    <ForeName>Bart L</ForeName>
                    <Initials>BL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>1U54HG006542</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>1U54RR023561-01A1</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>5RC1HL100021-02</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HL107738-01</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K08 HL107738</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01-AR049698</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AR041135</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01- AR41135</GrantID>
                    <Acronym>AR</Acronym>
                    <Agency>NIAMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U54 HG006542</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Howard Hughes Medical Institute</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008840">Microfilament Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C509041">TGFB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C509042">Tgfb2 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053781">Transforming Growth Factor beta2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C045556">fibrillin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2006 Aug 24;355(8):788-98</RefSource>
                <PMID Version="1">16928994</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2006 Apr 7;312(5770):117-21</RefSource>
                <PMID Version="1">16601194</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2007 Feb;13(2):204-10</RefSource>
                <PMID Version="1">17237794</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Biochem. 2007 Oct 15;102(3):593-608</RefSource>
                <PMID Version="1">17729308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Surg Pathol. 2009 Feb;33(2):194-201</RefSource>
                <PMID Version="1">18852674</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genesis. 2009 Feb;47(2):115-21</RefSource>
                <PMID Version="1">19165826</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pathol. 2009 May;218(1):131-42</RefSource>
                <PMID Version="1">19224541</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2009 Aug 11;120(6):526-32</RefSource>
                <PMID Version="1">19635970</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Development. 2009 Nov;136(22):3699-714</RefSource>
                <PMID Version="1">19855013</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Hum Genet. 2010 Aug;18(8):895-901</RefSource>
                <PMID Version="1">20389311</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2010 Aug;7(8):575-6</RefSource>
                <PMID Version="1">20676075</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2010 Oct 28;467(7319):1061-73</RefSource>
                <PMID Version="1">20981092</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transgenic Res. 2010 Dec;19(6):1069-82</RefSource>
                <PMID Version="1">20213136</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Feb;43(2):121-6</RefSource>
                <PMID Version="1">21217753</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2011 Apr 15;332(6027):358-61</RefSource>
                <PMID Version="1">21493862</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2011 Apr 15;332(6027):361-5</RefSource>
                <PMID Version="1">21493863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2011 May 19;473(7347):308-16</RefSource>
                <PMID Version="1">21593863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2012 Mar 1;122(3):873-85</RefSource>
                <PMID Version="1">22326956</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Biol. 2007 Jan 29;176(3):355-67</RefSource>
                <PMID Version="1">17242066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2001 Mar 15;10(6):591-7</RefSource>
                <PMID Version="1">11230178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2001 May;11(5):863-74</RefSource>
                <PMID Version="1">11337480</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2001 Jun 5;103(22):2745-52</RefSource>
                <PMID Version="1">11390347</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Biol. 2001 Jul 23;154(2):275-81</RefSource>
                <PMID Version="1">11470817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 Jan 24;278(4):2750-7</RefSource>
                <PMID Version="1">12429738</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2003 Mar;33(3):407-11</RefSource>
                <PMID Version="1">12598898</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2004 Jul;114(2):172-81</RefSource>
                <PMID Version="1">15254584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2004 Aug;36(8):855-60</RefSource>
                <PMID Version="1">15235604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1991 Jul 25;352(6333):337-9</RefSource>
                <PMID Version="1">1852208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 1955 Mar;11(3):321-42</RefSource>
                <PMID Version="1">14352380</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2004 Dec;114(11):1586-92</RefSource>
                <PMID Version="1">15546004</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2005 Mar;37(3):275-81</RefSource>
                <PMID Version="1">15731757</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Circ Cardiovasc Genet. 2012 Oct 1;5(5):593-4</RefSource>
                <PMID Version="1">23074340</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017545">Aortic Aneurysm, Thoracic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D057895">Haploinsufficiency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055947">Loeys-Dietz Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008382">Marfan Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008817">Mice, Mutant Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008840">Microfilament Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010375">Pedigree</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053781">Transforming Growth Factor beta2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000172">deficiency</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS453072</OtherID>
        <OtherID Source="NLM">PMC3616632</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2349</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2349</ArticleId>
            <ArticleId IdType="pubmed">22772368</ArticleId>
            <ArticleId IdType="pmc">PMC3616632</ArticleId>
            <ArticleId IdType="mid">NIHMS453072</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12739027</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>05</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>01</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0012-186X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>46</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Diabetologia</Title>
                <ISOAbbreviation>Diabetologia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Oxidant regulation of gene expression and neural tube development: Insights gained from diabetic pregnancy on molecular causes of neural tube defects.</ArticleTitle>
            <Pagination>
                <MedlinePgn>538-45</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">Maternal diabetes increases oxidative stress in embryos. Maternal diabetes also inhibits expression of embryonic genes, most notably, Pax-3, which is required for neural tube closure. Here we tested the hypothesis that oxidative stress inhibits expression of Pax-3, thereby providing a molecular basis for neural tube defects induced by diabetic pregnancy.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Maternal diabetes-induced oxidative stress was blocked with alpha-tocopherol (vitamin E), and oxidative stress was induced with the complex III electron transport inhibitor, antimycin A, using pregnant diabetic or non-diabetic mice, primary cultures of neurulating mouse embryo tissues, or differentiating P19 embryonal carcinoma cells. Pax-3 expression was assayed by quantitative RT-PCR, and neural tube defects were scored by visual inspection. Oxidation-induced DNA fragmentation in P19 cells was assayed by electrophoretic analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Maternal diabetes inhibited Pax-3 expression and increased neural tube defects, and alpha-tocopherol blocked these effects. In addition, induction of oxidative stress with antimycin A inhibited Pax-3 expression and increased neural tube defects. In cultured embryo tissues, high glucose-inhibited Pax-3 expression, and this effect was blocked by alpha-tocopherol and GSH-ethyl ester, and Pax-3 expression was inhibited by culture with antimycin A. In differentiating P19 cells, antimycin A inhibited Pax-3 induction but did not induce DNA strand breaks.</AbstractText>
                <AbstractText Label="CONCLUSION/INTERPRETATION" NlmCategory="CONCLUSIONS">Oxidative stress inhibits expression of Pax-3, a gene that is essential for neural tube closure. Impaired expression of essential developmental control genes could be the central mechanism by which neural tube defects occur during diabetic pregnancy, as well as other sources of oxidative stress.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>T I</ForeName>
                    <Initials>TI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Section on Molecular Biology and Complications, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horal</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>S K</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Loeken</LastName>
                    <ForeName>M R</ForeName>
                    <Initials>MR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DK52865</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DK58300</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2003</Year>
                <Month>03</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Diabetologia</MedlineTA>
            <NlmUniqueID>0006777</NlmUniqueID>
            <ISSNLinking>0012-186X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016877">Oxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051761">Paired Box Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>138016-91-8</RegistryNumber>
                <NameOfSubstance UI="C068686">Pax3 protein, mouse</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>642-15-9</RegistryNumber>
                <NameOfSubstance UI="D000968">Antimycin A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>H4N855PNZ1</RegistryNumber>
                <NameOfSubstance UI="D024502">alpha-Tocopherol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000968">Antimycin A</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004268">DNA-Binding Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003921">Diabetes Mellitus, Experimental</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004622">Embryo, Mammalian</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000002">abnormalities</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054278">Embryonal Carcinoma Stem Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005314">Embryonic and Fetal Development</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008813">Mice, Inbred ICR</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014411">Neoplastic Stem Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009436">Neural Tube Defects</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016877">Oxidants</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051761">Paired Box Transcription Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011254">Pregnancy in Diabetics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D014157">Transcription Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D024502">alpha-Tocopherol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2002</Year>
                <Month>Aug</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2002</Year>
                <Month>Nov</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2003</Year>
                <Month>Mar</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12739027</ArticleId>
            <ArticleId IdType="doi">10.1007/s00125-003-1063-2</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2000632</PMID>
        <DateCreated>
            <Year>1991</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1991</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0041-008X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>107</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1991</Year>
                        <Month>Mar</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hydronephrosis in mice exposed to TCDD-contaminated breast milk: identification of the peak period of sensitivity and assessment of potential recovery.</ArticleTitle>
            <Pagination>
                <MedlinePgn>413-28</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a potent inducer of hydronephrosis in both fetal and neonatal mice. A critical period of sensitivity to TCDD could not be identified for prenatally induced hydronephrosis since the urinary tract appeared equally sensitive throughout organogenesis. To identify the critical period of susceptibility for development of lactationally induced hydronephrosis in neonatal mice, as well as to characterize the potential for recovery from this renal lesion, dose-response and time-course studies were conducted in the postnatal period. Pregnant C57BL/6N mice were allowed natural delivery. In the dose-response phase of this investigation, mothers were administered 0, 3, 6, or 12 micrograms TCDD/kg once by gavage on Postnatal Day (PND) 1, 4, 8, or 14, and dams and pups were euthanized on PND 26. The kidneys were examined, and hydronephrotic severity was scored. The incidence and severity of hydronephrosis were significantly increased above controls only following treatment on PND 1 or 4, while on PND 8 the increase was marginal and pairwise tests were nonsignificant. Following treatment of dams on PND 1, the hydronephrotic response detected in 26-day-old pups was significantly greater than that for all later exposure days. In the time-course study, dams were given a single oral dose of 0 or 9 micrograms TCDD/kg on PND 1, and mothers and litters were subsequently euthanized on PND 7, 13, 19, or 26. Both hydronephrotic incidence and severity increased with time to euthanization following treatment on PND 1. Thus with the dosing regimen used in this study, recovery does not appear to occur between PNDs 7 and 26. Sex-related differences were observed, as the hydronephrotic response in males was generally greater than in females. In conclusion, the postnatal window of sensitivity during which TCDD can induce hydronephrosis is very narrow. Nonetheless, the hydronephrotic response induced during this early postnatal time is dramatic. Finally, PND 1 is the peak postnatal period of susceptibility for development of TCDD-induced hydronephrosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Couture-Haws</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Experimental Toxicology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Harris</LastName>
                    <ForeName>M W</ForeName>
                    <Initials>MW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McDonald</LastName>
                    <ForeName>M M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lockhart</LastName>
                    <ForeName>A C</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Birnbaum</LastName>
                    <ForeName>L S</ForeName>
                    <Initials>LS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>DO80M48B6O</RegistryNumber>
                <NameOfSubstance UI="D013749">Tetrachlorodibenzodioxin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000833">Animals, Suckling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006869">Hydronephrosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007668">Kidney</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000033">anatomy &amp; histology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007774">Lactation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000033">anatomy &amp; histology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008815">Mice, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008892">Milk</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013749">Tetrachlorodibenzodioxin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014551">Urinary Tract</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1991</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1991</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1991</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2000632</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22772369</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>07</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair.</ArticleTitle>
            <Pagination>
                <MedlinePgn>910-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2347</ELocationID>
            <Abstract>
                <AbstractText>Chronic kidney disease (CKD) represents a major health burden. Its central feature of renal fibrosis is not well understood. By exome sequencing, we identified mutations in FAN1 as a cause of karyomegalic interstitial nephritis (KIN), a disorder that serves as a model for renal fibrosis. Renal histology in KIN is indistinguishable from that of nephronophthisis, except for the presence of karyomegaly. The FAN1 protein has nuclease activity and acts in DNA interstrand cross-link (ICL) repair within the Fanconi anemia DNA damage response (DDR) pathway. We show that cells from individuals with FAN1 mutations have sensitivity to the ICL-inducing agent mitomycin C but do not exhibit chromosome breakage or cell cycle arrest after diepoxybutane treatment, unlike cells from individuals with Fanconi anemia. We complemented ICL sensitivity with wild-type FAN1 but not with cDNA having mutations found in individuals with KIN. Depletion of fan1 in zebrafish caused increased DDR, apoptosis and kidney cysts. Our findings implicate susceptibility to environmental genotoxins and inadequate DNA repair as novel mechanisms contributing to renal fibrosis and CKD.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Weibin</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Otto</LastName>
                    <ForeName>Edgar A</ForeName>
                    <Initials>EA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cluckey</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Airik</LastName>
                    <ForeName>Rannar</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hurd</LastName>
                    <ForeName>Toby W</ForeName>
                    <Initials>TW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chaki</LastName>
                    <ForeName>Moumita</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Diaz</LastName>
                    <ForeName>Katrina</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lach</LastName>
                    <ForeName>Francis P</ForeName>
                    <Initials>FP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bennett</LastName>
                    <ForeName>Geoffrey R</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gee</LastName>
                    <ForeName>Heon Yung</ForeName>
                    <Initials>HY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ghosh</LastName>
                    <ForeName>Amiya K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Natarajan</LastName>
                    <ForeName>Sivakumar</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thongthip</LastName>
                    <ForeName>Supawat</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Veturi</LastName>
                    <ForeName>Uma</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allen</LastName>
                    <ForeName>Susan J</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Janssen</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramaswami</LastName>
                    <ForeName>Gokul</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dixon</LastName>
                    <ForeName>Joanne</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burkhalter</LastName>
                    <ForeName>Felix</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spoendlin</LastName>
                    <ForeName>Martin</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moch</LastName>
                    <ForeName>Holger</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mihatsch</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verine</LastName>
                    <ForeName>Jerome</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reade</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soliman</LastName>
                    <ForeName>Hany</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Godin</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kiss</LastName>
                    <ForeName>Denes</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Monga</LastName>
                    <ForeName>Guido</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mazzucco</LastName>
                    <ForeName>Gianna</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Amann</LastName>
                    <ForeName>Kerstin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Artunc</LastName>
                    <ForeName>Ferruh</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Newland</LastName>
                    <ForeName>Ronald C</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wiech</LastName>
                    <ForeName>Thorsten</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zschiedrich</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huber</LastName>
                    <ForeName>Tobias B</ForeName>
                    <Initials>TB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Friedl</LastName>
                    <ForeName>Andreas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Slaats</LastName>
                    <ForeName>Gisela G</ForeName>
                    <Initials>GG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joles</LastName>
                    <ForeName>Jaap A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldschmeding</LastName>
                    <ForeName>Roel</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Washburn</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giles</LastName>
                    <ForeName>Rachel H</ForeName>
                    <Initials>RH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Levy</LastName>
                    <ForeName>Shawn</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smogorzewska</LastName>
                    <ForeName>Agata</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hildebrandt</LastName>
                    <ForeName>Friedhelm</ForeName>
                    <Initials>F</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DK020572</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DK068306</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DK090917</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DK091405</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>K99 DK091405</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DK068306</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Howard Hughes Medical Institute</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Howard Hughes Medical Institute</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C499905">FANCD2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D052236">Fanconi Anemia Complementation Group D2 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.-</RegistryNumber>
                <NameOfSubstance UI="D005090">Exodeoxyribonucleases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.-</RegistryNumber>
                <NameOfSubstance UI="C551063">FAN1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Kidney Dis. 1995 Feb;25(2):242-52</RefSource>
                <PMID Version="1">7847351</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2000 May;25(1):12-3</RefSource>
                <PMID Version="1">10802644</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2000 Jun;66(6):1945-57</RefSource>
                <PMID Version="1">10796874</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Kidney Dis. 2003 Jan;41(1):1-12</RefSource>
                <PMID Version="1">12500213</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2003 Aug;34(4):413-20</RefSource>
                <PMID Version="1">12872123</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2003 Nov 6;426(6962):83-7</RefSource>
                <PMID Version="1">14603322</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Cell. 2003 Dec;5(6):903-14</RefSource>
                <PMID Version="1">14667412</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pathol. 1974 Jul;113(3):147-50</RefSource>
                <PMID Version="1">4372331</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1976 Jun 10;261(5560):494-6</RefSource>
                <PMID Version="1">934283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Nephrol. 1979 Aug;12(2):54-62</RefSource>
                <PMID Version="1">527271</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Helv Paediatr Acta. 1980 Dec;35(6):509-30</RefSource>
                <PMID Version="1">7009503</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pathologe. 1994 Feb;15(1):44-8</RefSource>
                <PMID Version="1">8153075</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Kidney Dis. 1996 Jan;27(1):166</RefSource>
                <PMID Version="1">8546134</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 1996 Jun;58(6):1347-63</RefSource>
                <PMID Version="1">8651312</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2005 May;37(5):537-43</RefSource>
                <PMID Version="1">15852005</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 Jun;38(6):674-81</RefSource>
                <PMID Version="1">16682973</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pathol Res Pract. 2006;202(7):555-9</RefSource>
                <PMID Version="1">16678356</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diagn Cytopathol. 2007 Mar;35(3):179-82</RefSource>
                <PMID Version="1">17304531</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Cycle. 2007 Aug 1;6(15):1831-6</RefSource>
                <PMID Version="1">17671427</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2008 Mar;29(3):418-26</RefSource>
                <PMID Version="1">18076122</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Regul Integr Comp Physiol. 2008 Jun;294(6):R1847-55</RefSource>
                <PMID Version="1">18417652</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2008 Nov 6;456(7218):53-9</RefSource>
                <PMID Version="1">18987734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2008 Dec 1;17(23):3655-62</RefSource>
                <PMID Version="1">18723859</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2009 Jan;5(1):e1000353</RefSource>
                <PMID Version="1">19165332</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mutat Res. 2009 Jul 31;668(1-2):4-10</RefSource>
                <PMID Version="1">19622403</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2009 Dec 18;326(5960):1698-701</RefSource>
                <PMID Version="1">19965384</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Zebrafish. 2009 Dec;6(4):405-15</RefSource>
                <PMID Version="1">20047468</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hypertens. 2010 Jul;23(7):802-8</RefSource>
                <PMID Version="1">20360751</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Renal Physiol. 2010 Jul;299(1):F55-62</RefSource>
                <PMID Version="1">20462968</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2010 Jul 9;142(1):65-76</RefSource>
                <PMID Version="1">20603015</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2010 Jul 9;142(1):77-88</RefSource>
                <PMID Version="1">20603016</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell. 2010 Jul 9;39(1):36-47</RefSource>
                <PMID Version="1">20603073</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Pathol. 2010 Jun;30(3):240-2</RefSource>
                <PMID Version="1">20621605</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2010 Aug 6;329(5992):693-6</RefSource>
                <PMID Version="1">20671156</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Oct;42(10):840-50</RefSource>
                <PMID Version="1">20835237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21553-7</RefSource>
                <PMID Version="1">21115814</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2011 Apr 21;364(16):1533-43</RefSource>
                <PMID Version="1">21506742</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2012 Aug 3;150(3):533-48</RefSource>
                <PMID Version="1">22863007</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Nephrol. 2012 Sep;8(9):491</RefSource>
                <PMID Version="1">22825664</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002460">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004249">DNA Damage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004260">DNA Repair</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005090">Exodeoxyribonucleases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D052236">Fanconi Anemia Complementation Group D2 Protein</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055785">Gene Knockdown Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005808">Genes, Recessive</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005816">Genetic Complementation Test</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009395">Nephritis, Interstitial</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051436">Renal Insufficiency, Chronic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000002">abnormalities</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS385548</OtherID>
        <OtherID Source="NLM">PMC3412140</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>1</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2347</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2347</ArticleId>
            <ArticleId IdType="pubmed">22772369</ArticleId>
            <ArticleId IdType="pmc">PMC3412140</ArticleId>
            <ArticleId IdType="mid">NIHMS385548</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25304492</PMID>
        <DateCreated>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>29</Day>
        </DateCreated>
        <DateRevised>
            <Year>2015</Year>
            <Month>04</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-7786</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>234</Volume>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Jun</Month>
                        <Day>5</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chemico-biological interactions</Title>
                <ISOAbbreviation>Chem. Biol. Interact.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The aldo-keto reductases (AKRs): Overview.</ArticleTitle>
            <Pagination>
                <MedlinePgn>236-46</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2014.09.024</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0009-2797(14)00273-7</ELocationID>
            <Abstract>
                <AbstractText>The aldo-keto reductase (AKR) protein superfamily contains &gt;190 members that fall into 16 families and are found in all phyla. These enzymes reduce carbonyl substrates such as: sugar aldehydes; keto-steroids, keto-prostaglandins, retinals, quinones, and lipid peroxidation by-products. Exceptions include the reduction of steroid double bonds catalyzed by AKR1D enzymes (5β-reductases); and the oxidation of proximate carcinogen trans-dihydrodiol polycyclic aromatic hydrocarbons; while the β-subunits of potassium gated ion channels (AKR6 family) control Kv channel opening. AKRs are usually 37kDa monomers, have an (α/β)8-barrel motif, display large loops at the back of the barrel which govern substrate specificity, and have a conserved cofactor binding domain. AKRs catalyze an ordered bi bi kinetic mechanism in which NAD(P)H cofactor binds first and leaves last. In enzymes that favor NADPH, the rate of release of NADP(+) is governed by a slow isomerization step which places an upper limit on kcat. AKRs retain a conserved catalytic tetrad consisting of Tyr55, Asp50, Lys84, and His117 (AKR1C9 numbering). There is conservation of the catalytic mechanism with short-chain dehydrogenases/reductases (SDRs) even though they show different protein folds. There are 15 human AKRs of these AKR1B1, AKR1C1-1C3, AKR1D1, and AKR1B10 have been implicated in diabetic complications, steroid hormone dependent malignancies, bile acid deficiency and defects in retinoic acid signaling, respectively. Inhibitor programs exist world-wide to target each of these enzymes to treat the aforementioned disorders. Inherited mutations in AKR1C and AKR1D1 enzymes are implicated in defects in the development of male genitalia and bile acid deficiency, respectively, and occur in evolutionarily conserved amino acids. The human AKRs have a large number of nsSNPs and splice variants, but in many instances functional genomics is lacking. AKRs and their variants are now poised to be interrogated using modern genomic and informatics approaches to determine their association with human health and disease.</AbstractText>
                <CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Penning</LastName>
                    <ForeName>Trevor M</ForeName>
                    <Initials>TM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center of Excellence in Environmental Toxicology, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: penning@upenn.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 ES013508</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA039504</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA090744</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DK047015</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Chem Biol Interact</MedlineTA>
            <NlmUniqueID>0227276</NlmUniqueID>
            <ISSNLinking>0009-2797</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2014;9(2):e87096</RefSource>
                <PMID Version="1">24533052</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Cancer. 2014 Mar 18;110(6):1506-16</RefSource>
                <PMID Version="1">24569460</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest Ophthalmol Vis Sci. 2014 May;55(5):2853-61</RefSource>
                <PMID Version="1">24677107</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Invest New Drugs. 2014 Oct;32(5):860-70</RefSource>
                <PMID Version="1">24981575</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 1998 Oct 8;41(21):4118-29</RefSource>
                <PMID Version="1">9767647</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1999 Jun 15;38(24):7856-64</RefSource>
                <PMID Version="1">10387026</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Endocrinol Metab. 2004 Nov;15(9):432-8</RefSource>
                <PMID Version="1">15519890</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2005 Mar 1;11(5):1776-85</RefSource>
                <PMID Version="1">15755999</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Endocrinol. 2006 Feb;20(2):444-58</RefSource>
                <PMID Version="1">16179381</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Endocrinol. 2006 Mar 27;248(1-2):126-35</RefSource>
                <PMID Version="1">16338060</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2006 Oct 1;399(1):101-9</RefSource>
                <PMID Version="1">16787387</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Pharmacol Toxicol. 2007;47:263-92</RefSource>
                <PMID Version="1">16970545</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Pharmacol Toxicol. 2007;47:293-322</RefSource>
                <PMID Version="1">17009925</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2007 Jul 27;359(2):269-76</RefSource>
                <PMID Version="1">17540341</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2007 Sep 7;282(36):25986-92</RefSource>
                <PMID Version="1">17591773</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2007 Nov 16;282(46):33484-93</RefSource>
                <PMID Version="1">17848571</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 2008 Jan 15;75(2):484-93</RefSource>
                <PMID Version="1">17950253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20764-9</RefSource>
                <PMID Version="1">18087047</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Res Toxicol. 2008 May;21(5):1134-42</RefSource>
                <PMID Version="1">18416522</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2001 Jan 26;276(4):2890-7</RefSource>
                <PMID Version="1">11060293</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetes Care. 2001 Oct;24(10):1776-82</RefSource>
                <PMID Version="1">11574441</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Jul 5;277(27):24799-808</RefSource>
                <PMID Version="1">11978787</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2003 Jan 15;63(2):505-12</RefSource>
                <PMID Version="1">12543809</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 2003 Feb 1;143-144:289-97</RefSource>
                <PMID Version="1">12604215</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 2003 Feb 1;143-144:621-31</RefSource>
                <PMID Version="1">12604248</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2003 Jul;144(7):2922-32</RefSource>
                <PMID Version="1">12810547</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Med Chem. 2003 Aug;10(15):1375-87</RefSource>
                <PMID Version="1">12871135</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gut. 2003 Oct;52(10):1494-9</RefSource>
                <PMID Version="1">12970144</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 2004 Mar 2;43(8):2188-98</RefSource>
                <PMID Version="1">14979715</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 2004 Apr;40(4):716-8</RefSource>
                <PMID Version="1">15030995</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Med. 1975;26:521-36</RefSource>
                <PMID Version="1">238458</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1983 Jan 20;308(3):119-25</RefSource>
                <PMID Version="1">6401351</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Chem. 1984 Mar;27(3):255-6</RefSource>
                <PMID Version="1">6422042</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1984 Jun 25;259(12):7519-24</RefSource>
                <PMID Version="1">6736016</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacology. 1985;31(2):88-96</RefSource>
                <PMID Version="1">3927328</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1989 Jun 5;264(16):9547-51</RefSource>
                <PMID Version="1">2498333</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Diabetes Complications. 2010 Sep-Oct;24(5):354-60</RefSource>
                <PMID Version="1">19748287</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Med Chem. 2010 Nov;45(11):5309-17</RefSource>
                <PMID Version="1">20850205</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabetologia. 2011 May;54(5):1242-51</RefSource>
                <PMID Version="1">21267539</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 2011 May 30;191(1-3):250-4</RefSource>
                <PMID Version="1">21185810</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nat Prod. 2011 May 27;74(5):1201-6</RefSource>
                <PMID Version="1">21561086</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antioxid Redox Signal. 2011 Aug 1;15(3):691-718</RefSource>
                <PMID Version="1">20973619</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2011 Aug 12;89(2):201-18</RefSource>
                <PMID Version="1">21802064</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2012 Mar 1;442(2):273-82</RefSource>
                <PMID Version="1">22329800</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Steroid Biochem Mol Biol. 2012 May;130(1-2):7-15</RefSource>
                <PMID Version="1">22265960</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pflugers Arch. 2012 Jun;463(6):799-818</RefSource>
                <PMID Version="1">22426702</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Diabet Med. 2012 Dec;29(12):1529-33</RefSource>
                <PMID Version="1">22507139</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 2013 Feb 25;202(1-3):153-8</RefSource>
                <PMID Version="1">23298867</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2013 Sep;34(9):2090-8</RefSource>
                <PMID Version="1">23689354</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2013 Oct 15;19(20):5613-25</RefSource>
                <PMID Version="1">23995860</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1992 Jul 3;257(5066):81-4</RefSource>
                <PMID Version="1">1621098</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1992 Dec 5;267(34):24841-7</RefSource>
                <PMID Version="1">1447221</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pediatr. 1994 Feb;124(2):234-8</RefSource>
                <PMID Version="1">8301429</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Biochem. 1994 Jan 15;219(1-2):357-63</RefSource>
                <PMID Version="1">7508385</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1994 Mar 1;33(8):2021-32</RefSource>
                <PMID Version="1">8117659</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2517-21</RefSource>
                <PMID Version="1">8146147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Struct Biol. 1995 Aug;2(8):687-92</RefSource>
                <PMID Version="1">7552731</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1995 Nov 7;34(44):14356-65</RefSource>
                <PMID Version="1">7578039</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1995 Nov 7;34(44):14374-84</RefSource>
                <PMID Version="1">7578041</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 1995 Dec 26;217(3):741-6</RefSource>
                <PMID Version="1">8554593</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1996 Aug 20;35(33):10702-11</RefSource>
                <PMID Version="1">8718859</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 1997 Feb 1;349(9048):329</RefSource>
                <PMID Version="1">9024384</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1997 Sep 15;326 ( Pt 3):625-36</RefSource>
                <PMID Version="1">9307009</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1997 Sep 15;54(6):639-47</RefSource>
                <PMID Version="1">9310340</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1998 Mar 10;37(10):3538-48</RefSource>
                <PMID Version="1">9521675</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1998 May 12;37(19):6781-90</RefSource>
                <PMID Version="1">9578563</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Horm Metab Res. 1998 Apr;30(4):227-30</RefSource>
                <PMID Version="1">9623639</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1998 Jul 7;37(27):9695-703</RefSource>
                <PMID Version="1">9657682</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 1998 Aug 4;37(31):11003-11</RefSource>
                <PMID Version="1">9692994</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2008 Jun 13;283(24):16830-9</RefSource>
                <PMID Version="1">18407998</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Sci. 2008 Jul;107(3):340-8</RefSource>
                <PMID Version="1">18612195</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Endocrinol. 2009 Mar 25;301(1-2):191-8</RefSource>
                <PMID Version="1">18848863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Protoc. 2009;4(7):1073-81</RefSource>
                <PMID Version="1">19561590</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2009;4(12):e8147</RefSource>
                <PMID Version="1">19997560</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):177-87</RefSource>
                <PMID Version="1">20036328</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2010 Aug 6;285(32):24529-37</RefSource>
                <PMID Version="1">20522910</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FEBS Lett. 1999 Dec 3;462(3):335-40</RefSource>
                <PMID Version="1">10622721</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochemistry. 2000 Jan 11;39(1):102-9</RefSource>
                <PMID Version="1">10625484</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Xenobiotica. 2000 Aug;30(8):755-69</RefSource>
                <PMID Version="1">11037109</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurochem. 2000 Nov;75(5):1986-96</RefSource>
                <PMID Version="1">11032888</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Int. 2000 Oct;42(5):594</RefSource>
                <PMID Version="1">11059561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 2000 Oct 1;351(Pt 1):67-77</RefSource>
                <PMID Version="1">10998348</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Biol Interact. 2001 Jan 30;130-132(1-3):617-25</RefSource>
                <PMID Version="1">11306080</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">NIHMS640041 [Available on 06/05/16]</OtherID>
        <OtherID Source="NLM">PMC4388799 [Available on 06/05/16]</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Hydroxysteroid dehydrogenases</Keyword>
            <Keyword MajorTopicYN="N">Potassium channels</Keyword>
            <Keyword MajorTopicYN="N">Quinone reductase</Keyword>
            <Keyword MajorTopicYN="N">Steroid 5β-reductase</Keyword>
            <Keyword MajorTopicYN="N">Xenobiotics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>5</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25304492</ArticleId>
            <ArticleId IdType="pii">S0009-2797(14)00273-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.cbi.2014.09.024</ArticleId>
            <ArticleId IdType="pmc">PMC4388799</ArticleId>
            <ArticleId IdType="mid">NIHMS640041</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22772371</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>07</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>916-21</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2348</ELocationID>
            <Abstract>
                <AbstractText>A predisposition for thoracic aortic aneurysms leading to acute aortic dissections can be inherited in families in an autosomal dominant manner. Genome-wide linkage analysis of two large unrelated families with thoracic aortic disease followed by whole-exome sequencing of affected relatives identified causative mutations in TGFB2. These mutations-a frameshift mutation in exon 6 and a nonsense mutation in exon 4-segregated with disease with a combined logarithm of odds (LOD) score of 7.7. Sanger sequencing of 276 probands from families with inherited thoracic aortic disease identified 2 additional TGFB2 mutations. TGFB2 encodes transforming growth factor (TGF)-β2, and the mutations are predicted to cause haploinsufficiency for TGFB2; however, aortic tissue from cases paradoxically shows increased TGF-β2 expression and immunostaining. Thus, haploinsufficiency for TGFB2 predisposes to thoracic aortic disease, suggesting that the initial pathway driving disease is decreased cellular TGF-β2 levels leading to a secondary increase in TGF-β2 production in the diseased aorta.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Boileau</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM) U698, Hôpital Bichat, Paris, France. catherine.boileau@inserm.fr</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Dong-Chuan</ForeName>
                    <Initials>DC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hanna</LastName>
                    <ForeName>Nadine</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Regalado</LastName>
                    <ForeName>Ellen S</ForeName>
                    <Initials>ES</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Detaint</LastName>
                    <ForeName>Delphine</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Limin</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varret</LastName>
                    <ForeName>Mathilde</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prakash</LastName>
                    <ForeName>Siddharth K</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Alexander H</ForeName>
                    <Initials>AH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>d'Indy</LastName>
                    <ForeName>Hyacintha</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Braverman</LastName>
                    <ForeName>Alan C</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grandchamp</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwartler</LastName>
                    <ForeName>Callie S</ForeName>
                    <Initials>CS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gouya</LastName>
                    <ForeName>Laurent</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santos-Cortez</LastName>
                    <ForeName>Regie Lyn P</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abifadel</LastName>
                    <ForeName>Marianne</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leal</LastName>
                    <ForeName>Suzanne M</ForeName>
                    <Initials>SM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muti</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shendure</LastName>
                    <ForeName>Jay</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gross</LastName>
                    <ForeName>Marie-Sylvie</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rieder</LastName>
                    <ForeName>Mark J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vahanian</LastName>
                    <ForeName>Alec</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nickerson</LastName>
                    <ForeName>Deborah A</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michel</LastName>
                    <ForeName>Jean Baptiste</ForeName>
                    <Initials>JB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jondeau</LastName>
                    <ForeName>Guillaume</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Milewicz</LastName>
                    <ForeName>Dianna M</ForeName>
                    <Initials>DM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>090532</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>P50 HL083794</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P50HL083794-01</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL062594</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL109942</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL62594</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 RR024148</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1 RR024148</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018389">Codon, Nonsense</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C509041">TGFB2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053781">Transforming Growth Factor beta2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pathol. 2009 May;218(1):131-42</RefSource>
                <PMID Version="1">19224541</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2008 Nov;29(11):E284-95</RefSource>
                <PMID Version="1">18781618</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2002 Jul;31(3):241-7</RefSource>
                <PMID Version="1">12053178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2002;18 Suppl 1:S189-98</RefSource>
                <PMID Version="1">12169547</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biotechnol Lett. 2003 Dec;25(24):2079-83</RefSource>
                <PMID Version="1">14969412</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 2004 May 14;94(9):1195-202</RefSource>
                <PMID Version="1">15059931</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2004 Aug;36(8):855-60</RefSource>
                <PMID Version="1">15235604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 1993 Jul;53(1):252-63</RefSource>
                <PMID Version="1">8317490</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 1995 Jun;56(6):1506-7</RefSource>
                <PMID Version="1">7762577</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Development. 1997 Jul;124(13):2659-70</RefSource>
                <PMID Version="1">9217007</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 1998 Jul;63(1):259-66</RefSource>
                <PMID Version="1">9634505</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2005 Feb 1;21(3):405-7</RefSource>
                <PMID Version="1">15347576</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Thorac Cardiovasc Surg. 2006 Mar;131(3):671-8</RefSource>
                <PMID Version="1">16515922</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2006 Apr 7;312(5770):117-21</RefSource>
                <PMID Version="1">16601194</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2006 Aug 24;355(8):788-98</RefSource>
                <PMID Version="1">16928994</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1248-58</RefSource>
                <PMID Version="1">17379839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2007 Sep;81(3):454-66</RefSource>
                <PMID Version="1">17701892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2012 Mar 1;122(3):873-85</RefSource>
                <PMID Version="1">22326956</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FEBS Lett. 2009 Feb 4;583(3):499-505</RefSource>
                <PMID Version="1">19162024</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet A. 2009 May;149A(5):854-60</RefSource>
                <PMID Version="1">19353630</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2009 Dec 22;120(25):2541-9</RefSource>
                <PMID Version="1">19996017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 Jan;42(1):30-5</RefSource>
                <PMID Version="1">19915526</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Mar 1;26(5):589-95</RefSource>
                <PMID Version="1">20080505</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2010 Apr 6;121(13):e266-369</RefSource>
                <PMID Version="1">20233780</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2010 Jul;47(7):476-85</RefSource>
                <PMID Version="1">20591885</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiovasc Res. 2010 Dec 1;88(3):520-9</RefSource>
                <PMID Version="1">20628007</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2010 Dec 10;87(6):743-56</RefSource>
                <PMID Version="1">21092924</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiovasc Res. 2011 Feb 1;89(2):446-56</RefSource>
                <PMID Version="1">20829218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Feb;43(2):121-6</RefSource>
                <PMID Version="1">21217753</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 May;43(5):491-8</RefSource>
                <PMID Version="1">21478889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Jun;43(6):585-9</RefSource>
                <PMID Version="1">21572417</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet A. 2011 Sep;155A(9):2125-30</RefSource>
                <PMID Version="1">21815248</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 2011 Sep 2;109(6):680-6</RefSource>
                <PMID Version="1">21778426</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Med Genet. 2012 Jan;49(1):47-57</RefSource>
                <PMID Version="1">22167769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Circ Cardiovasc Genet. 2012 Oct 1;5(5):593-4</RefSource>
                <PMID Version="1">23074340</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000784">Aneurysm, Dissecting</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017545">Aortic Aneurysm, Thoracic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018389">Codon, Nonsense</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059472">Exome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016368">Frameshift Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055106">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D057895">Haploinsufficiency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008126">Lod Score</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008382">Marfan Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010375">Pedigree</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053781">Transforming Growth Factor beta2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS386390</OtherID>
        <OtherID Source="NLM">PMC4033668</OtherID>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Gabriel</LastName>
                <ForeName>Stacey B</ForeName>
                <Initials>SB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Altshuler</LastName>
                <ForeName>David M</ForeName>
                <Initials>DM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abecasis</LastName>
                <ForeName>Gonçalo R</ForeName>
                <Initials>GR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Allayee</LastName>
                <ForeName>Hooman</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cresci</LastName>
                <ForeName>Sharon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Daly</LastName>
                <ForeName>Mark J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>de Bakker</LastName>
                <ForeName>Paul I W</ForeName>
                <Initials>PI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Depristo</LastName>
                <ForeName>Mark A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Do</LastName>
                <ForeName>Ron</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donnelly</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Farlow</LastName>
                <ForeName>Deborah N</ForeName>
                <Initials>DN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fennell</LastName>
                <ForeName>Tim</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Garimella</LastName>
                <ForeName>Kiran</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hazen</LastName>
                <ForeName>Stanley L</ForeName>
                <Initials>SL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hu</LastName>
                <ForeName>Youna</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jordan</LastName>
                <ForeName>Daniel M</ForeName>
                <Initials>DM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jun</LastName>
                <ForeName>Goo</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kathiresan</LastName>
                <ForeName>Sekar</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kang</LastName>
                <ForeName>Hyun Min</ForeName>
                <Initials>HM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kiezun</LastName>
                <ForeName>Adam</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lettre</LastName>
                <ForeName>Guillaume</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Bingshan</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Mingyao</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Newton-Cheh</LastName>
                <ForeName>Christopher H</ForeName>
                <Initials>CH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Padmanabhan</LastName>
                <ForeName>Sandosh</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peloso</LastName>
                <ForeName>Gina</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pulit</LastName>
                <ForeName>Sara</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rader</LastName>
                <ForeName>Daniel J</ForeName>
                <Initials>DJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reich</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reilly</LastName>
                <ForeName>Muredach P</ForeName>
                <Initials>MP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rivas</LastName>
                <ForeName>Manuel A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schwartz</LastName>
                <ForeName>Steve</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Scott</LastName>
                <ForeName>Laura</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siscovick</LastName>
                <ForeName>David S</ForeName>
                <Initials>DS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spertus</LastName>
                <ForeName>John A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stitziel</LastName>
                <ForeName>Nathaniel O</ForeName>
                <Initials>NO</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stoletzki</LastName>
                <ForeName>Nina</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sunyaev</LastName>
                <ForeName>Shamil R</ForeName>
                <Initials>SR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Voight</LastName>
                <ForeName>Benjamin F</ForeName>
                <Initials>BF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Willer</LastName>
                <ForeName>Cristen J</ForeName>
                <Initials>CJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rich</LastName>
                <ForeName>Stephen S</ForeName>
                <Initials>SS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Akylbekova</LastName>
                <ForeName>Ermeg</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Atwood</LastName>
                <ForeName>Larry D</ForeName>
                <Initials>LD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ballantyne</LastName>
                <ForeName>Christie M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barbalic</LastName>
                <ForeName>Maja</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barr</LastName>
                <ForeName>R Graham</ForeName>
                <Initials>RG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Benjamin</LastName>
                <ForeName>Emelia J</ForeName>
                <Initials>EJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bis</LastName>
                <ForeName>Joshua</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Boerwinkle</LastName>
                <ForeName>Eric</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bowden</LastName>
                <ForeName>Donald W</ForeName>
                <Initials>DW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brody</LastName>
                <ForeName>Jennifer</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Budoff</LastName>
                <ForeName>Matthew</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burke</LastName>
                <ForeName>Greg</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Buxbaum</LastName>
                <ForeName>Sarah</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carr</LastName>
                <ForeName>Jeff</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chen</LastName>
                <ForeName>Donna T</ForeName>
                <Initials>DT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chen</LastName>
                <ForeName>Ida Y</ForeName>
                <Initials>IY</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chen</LastName>
                <ForeName>Wei-Min</ForeName>
                <Initials>WM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Concannon</LastName>
                <ForeName>Pat</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crosby</LastName>
                <ForeName>Jacy</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cupples</LastName>
                <ForeName>L Adrienne</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>D'Agostino</LastName>
                <ForeName>Ralph</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>DeStefano</LastName>
                <ForeName>Anita L</ForeName>
                <Initials>AL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dreisbach</LastName>
                <ForeName>Albert</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dupuis</LastName>
                <ForeName>Josée</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Durda</LastName>
                <ForeName>J Peter</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ellis</LastName>
                <ForeName>Jaclyn</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Folsom</LastName>
                <ForeName>Aaron R</ForeName>
                <Initials>AR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fornage</LastName>
                <ForeName>Myriam</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fox</LastName>
                <ForeName>Caroline S</ForeName>
                <Initials>CS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fox</LastName>
                <ForeName>Ervin</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Funari</LastName>
                <ForeName>Vincent</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ganesh</LastName>
                <ForeName>Santhi K</ForeName>
                <Initials>SK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gardin</LastName>
                <ForeName>Julius</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goff</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon</LastName>
                <ForeName>Ora</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grody</LastName>
                <ForeName>Wayne</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gross</LastName>
                <ForeName>Myron</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Guo</LastName>
                <ForeName>Xiuqing</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hall</LastName>
                <ForeName>Ira M</ForeName>
                <Initials>IM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heard-Costa</LastName>
                <ForeName>Nancy L</ForeName>
                <Initials>NL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heckbert</LastName>
                <ForeName>Susan R</ForeName>
                <Initials>SR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heintz</LastName>
                <ForeName>Nicholas</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Herrington</LastName>
                <ForeName>David M</ForeName>
                <Initials>DM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hickson</LastName>
                <ForeName>DeMarc</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Huang</LastName>
                <ForeName>Jie</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hwang</LastName>
                <ForeName>Shih-Jen</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jacobs</LastName>
                <ForeName>David R</ForeName>
                <Initials>DR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jenny</LastName>
                <ForeName>Nancy S</ForeName>
                <Initials>NS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Johnson</LastName>
                <ForeName>Andrew D</ForeName>
                <Initials>AD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Johnson</LastName>
                <ForeName>Craig W</ForeName>
                <Initials>CW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kawut</LastName>
                <ForeName>Steven</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kronmal</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kurz</LastName>
                <ForeName>Raluca</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Ethan M</ForeName>
                <Initials>EM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Leslie A</ForeName>
                <Initials>LA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Larson</LastName>
                <ForeName>Martin G</ForeName>
                <Initials>MG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lawson</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lewis</LastName>
                <ForeName>Cora E</ForeName>
                <Initials>CE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Levy</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Dalin</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Honghuang</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Chunyu</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Jiankang</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Kiang</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Xiaoming</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Yongmei</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Longstreth</LastName>
                <ForeName>William T</ForeName>
                <Initials>WT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Loria</LastName>
                <ForeName>Cay</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lumley</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lunetta</LastName>
                <ForeName>Kathryn</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mackey</LastName>
                <ForeName>Aaron J</ForeName>
                <Initials>AJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mackey</LastName>
                <ForeName>Rachel</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manichaikul</LastName>
                <ForeName>Ani</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maxwell</LastName>
                <ForeName>Taylor</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McKnight</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meigs</LastName>
                <ForeName>James B</ForeName>
                <Initials>JB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morrison</LastName>
                <ForeName>Alanna C</ForeName>
                <Initials>AC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Musani</LastName>
                <ForeName>Solomon K</ForeName>
                <Initials>SK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mychaleckyj</LastName>
                <ForeName>Josyf C</ForeName>
                <Initials>JC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nettleton</LastName>
                <ForeName>Jennifer A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>North</LastName>
                <ForeName>Kari</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Donnell</LastName>
                <ForeName>Christopher J</ForeName>
                <Initials>CJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Leary</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ong</LastName>
                <ForeName>Frank</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Palmas</LastName>
                <ForeName>Walter</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pankow</LastName>
                <ForeName>James S</ForeName>
                <Initials>JS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pankratz</LastName>
                <ForeName>Nathan D</ForeName>
                <Initials>ND</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paul</LastName>
                <ForeName>Shom</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perez</LastName>
                <ForeName>Marco</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Person</LastName>
                <ForeName>Sharina D</ForeName>
                <Initials>SD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Polak</LastName>
                <ForeName>Joseph</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Post</LastName>
                <ForeName>Wendy S</ForeName>
                <Initials>WS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Psaty</LastName>
                <ForeName>Bruce M</ForeName>
                <Initials>BM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Quinlan</LastName>
                <ForeName>Aaron R</ForeName>
                <Initials>AR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Raffel</LastName>
                <ForeName>Leslie J</ForeName>
                <Initials>LJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ramachandran</LastName>
                <ForeName>Vasan S</ForeName>
                <Initials>VS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reiner</LastName>
                <ForeName>Alexander P</ForeName>
                <Initials>AP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rice</LastName>
                <ForeName>Kenneth</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rotter</LastName>
                <ForeName>Jerome I</ForeName>
                <Initials>JI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sanders</LastName>
                <ForeName>Jill P</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schreiner</LastName>
                <ForeName>Pamela</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seshadri</LastName>
                <ForeName>Sudha</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shea</LastName>
                <ForeName>Steve</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sidney</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Silverstein</LastName>
                <ForeName>Kevin</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siscovick</LastName>
                <ForeName>David S</ForeName>
                <Initials>DS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Smith</LastName>
                <ForeName>Nicholas L</ForeName>
                <Initials>NL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sotoodehnia</LastName>
                <ForeName>Nona</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Srinivasan</LastName>
                <ForeName>Asoke</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taylor</LastName>
                <ForeName>Herman A</ForeName>
                <Initials>HA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taylor</LastName>
                <ForeName>Kent</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thomas</LastName>
                <ForeName>Fridtjof</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tracy</LastName>
                <ForeName>Russell P</ForeName>
                <Initials>RP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tsai</LastName>
                <ForeName>Michael Y</ForeName>
                <Initials>MY</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Volcik</LastName>
                <ForeName>Kelly A</ForeName>
                <Initials>KA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wassel</LastName>
                <ForeName>Chrstina L</ForeName>
                <Initials>CL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Watson</LastName>
                <ForeName>Karol</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wei</LastName>
                <ForeName>Gina</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>White</LastName>
                <ForeName>Wendy</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wiggins</LastName>
                <ForeName>Kerri L</ForeName>
                <Initials>KL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilk</LastName>
                <ForeName>Jemma B</ForeName>
                <Initials>JB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Williams</LastName>
                <ForeName>O Dale</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilson</LastName>
                <ForeName>Gregory</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilson</LastName>
                <ForeName>James G</ForeName>
                <Initials>JG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wolf</LastName>
                <ForeName>Phillip</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zakai</LastName>
                <ForeName>Neil A</ForeName>
                <Initials>NA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hardy</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meschia</LastName>
                <ForeName>James F</ForeName>
                <Initials>JF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nalls</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rich</LastName>
                <ForeName>Stephen S</ForeName>
                <Initials>SS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Singleton</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Worrall</LastName>
                <ForeName>Brad</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bamshad</LastName>
                <ForeName>Michael J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barnes</LastName>
                <ForeName>Kathleen C</ForeName>
                <Initials>KC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abdulhamid</LastName>
                <ForeName>Ibrahim</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Accurso</LastName>
                <ForeName>Frank</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Beaty</LastName>
                <ForeName>Terri</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bigham</LastName>
                <ForeName>Abigail</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Black</LastName>
                <ForeName>Phillip</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bleecker</LastName>
                <ForeName>Eugene</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Buckingham</LastName>
                <ForeName>Kati</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cairns</LastName>
                <ForeName>Anne Marie</ForeName>
                <Initials>AM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chen</LastName>
                <ForeName>Wei-Min</ForeName>
                <Initials>WM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Caplan</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chatfield</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chidekel</LastName>
                <ForeName>Aaron</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cho</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Christiani</LastName>
                <ForeName>David C</ForeName>
                <Initials>DC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crapo</LastName>
                <ForeName>James D</ForeName>
                <Initials>JD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crouch</LastName>
                <ForeName>Julia</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Daley</LastName>
                <ForeName>Denise</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dang</LastName>
                <ForeName>Anthony</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dang</LastName>
                <ForeName>Hong</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>De Paula</LastName>
                <ForeName>Alicia</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>DeCelie-Germana</LastName>
                <ForeName>Joan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dozor</LastName>
                <ForeName>Allen</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Drumm</LastName>
                <ForeName>Mitch</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dyson</LastName>
                <ForeName>Maynard</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Emerson</LastName>
                <ForeName>Julia</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Emond</LastName>
                <ForeName>Mary J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ferkol</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fink</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Foster</LastName>
                <ForeName>Cassandra</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Froh</LastName>
                <ForeName>Deborah</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gao</LastName>
                <ForeName>Li</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gershan</LastName>
                <ForeName>William</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gibson</LastName>
                <ForeName>Ronald L</ForeName>
                <Initials>RL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Godwin</LastName>
                <ForeName>Elizabeth</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gondor</LastName>
                <ForeName>Magdalen</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gutierrez</LastName>
                <ForeName>Hector</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hansel</LastName>
                <ForeName>Nadia N</ForeName>
                <Initials>NN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hassoun</LastName>
                <ForeName>Paul M</ForeName>
                <Initials>PM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hiatt</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hokanson</LastName>
                <ForeName>John E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Howenstine</LastName>
                <ForeName>Michelle</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hummer</LastName>
                <ForeName>Laura K</ForeName>
                <Initials>LK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kanga</LastName>
                <ForeName>Jamshed</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kim</LastName>
                <ForeName>Yoonhee</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Knowles</LastName>
                <ForeName>Michael R</ForeName>
                <Initials>MR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Konstan</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lahiri</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Laird</LastName>
                <ForeName>Nan</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Christoph</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Lin</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Xihong</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Louie</LastName>
                <ForeName>Tin L</ForeName>
                <Initials>TL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lynch</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Make</LastName>
                <ForeName>Barry</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martin</LastName>
                <ForeName>Thomas R</ForeName>
                <Initials>TR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathai</LastName>
                <ForeName>Steve C</ForeName>
                <Initials>SC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathias</LastName>
                <ForeName>Rasika A</ForeName>
                <Initials>RA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McNamara</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McNamara</LastName>
                <ForeName>Sharon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meyers</LastName>
                <ForeName>Deborah</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Millard</LastName>
                <ForeName>Susan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mogayzel</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moss</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Murray</LastName>
                <ForeName>Tanda</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nielson</LastName>
                <ForeName>Dennis</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Noyes</LastName>
                <ForeName>Blakeslee</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Neal</LastName>
                <ForeName>Wanda</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Orenstein</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Sullivan</LastName>
                <ForeName>Brian</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pace</LastName>
                <ForeName>Rhonda</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pare</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Parker</LastName>
                <ForeName>H Worth</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Passero</LastName>
                <ForeName>Mary Ann</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perkett</LastName>
                <ForeName>Elizabeth</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prestridge</LastName>
                <ForeName>Adrienne</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rafaels</LastName>
                <ForeName>Nicholas M</ForeName>
                <Initials>NM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ramsey</LastName>
                <ForeName>Bonnie</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Regan</LastName>
                <ForeName>Elizabeth</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ren</LastName>
                <ForeName>Clement</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Retsch-Bogart</LastName>
                <ForeName>George</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rock</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosen</LastName>
                <ForeName>Antony</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosenfeld</LastName>
                <ForeName>Margaret</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruczinski</LastName>
                <ForeName>Ingo</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sanford</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schaeffer</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sell</LastName>
                <ForeName>Cindy</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sheehan</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Silverman</LastName>
                <ForeName>Edwin K</ForeName>
                <Initials>EK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sin</LastName>
                <ForeName>Don</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spencer</LastName>
                <ForeName>Terry</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stonebraker</LastName>
                <ForeName>Jackie</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tabor</LastName>
                <ForeName>Holly K</ForeName>
                <Initials>HK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Varlotta</LastName>
                <ForeName>Laurie</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vergara</LastName>
                <ForeName>Candelaria I</ForeName>
                <Initials>CI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weiss</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wigley</LastName>
                <ForeName>Fred</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wise</LastName>
                <ForeName>Robert A</ForeName>
                <Initials>RA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wright</LastName>
                <ForeName>Fred A</ForeName>
                <Initials>FA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wurfel</LastName>
                <ForeName>Mark M</ForeName>
                <Initials>MM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zanni</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zou</LastName>
                <ForeName>Fei</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nickerson</LastName>
                <ForeName>Deborah A</ForeName>
                <Initials>DA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rieder</LastName>
                <ForeName>Mark J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Green</LastName>
                <ForeName>Phil</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shendure</LastName>
                <ForeName>Jay</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Akey</LastName>
                <ForeName>Joshua M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bamshad</LastName>
                <ForeName>Michael J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bustamante</LastName>
                <ForeName>Carlos D</ForeName>
                <Initials>CD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crosslin</LastName>
                <ForeName>David R</ForeName>
                <Initials>DR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eichler</LastName>
                <ForeName>Evan E</ForeName>
                <Initials>EE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fox</LastName>
                <ForeName>P Keolu</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon</LastName>
                <ForeName>Adam</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gravel</LastName>
                <ForeName>Simon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jarvik</LastName>
                <ForeName>Gail P</ForeName>
                <Initials>GP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Johnsen</LastName>
                <ForeName>Jill M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kan</LastName>
                <ForeName>Mengyuan</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kenny</LastName>
                <ForeName>Eimear E</ForeName>
                <Initials>EE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kidd</LastName>
                <ForeName>Jeffrey M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lara-Garduno</LastName>
                <ForeName>Fremiet</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leal</LastName>
                <ForeName>Suzanne M</ForeName>
                <Initials>SM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Dajiang J</ForeName>
                <Initials>DJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McGee</LastName>
                <ForeName>Sean</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paeper</LastName>
                <ForeName>Bryan</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Robertson</LastName>
                <ForeName>Peggy D</ForeName>
                <Initials>PD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Smith</LastName>
                <ForeName>Joshua D</ForeName>
                <Initials>JD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Turner</LastName>
                <ForeName>Emily H</ForeName>
                <Initials>EH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wang</LastName>
                <ForeName>Gao</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jackson</LastName>
                <ForeName>Rebecca</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>North</LastName>
                <ForeName>Kari</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peters</LastName>
                <ForeName>Ulrike</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carlson</LastName>
                <ForeName>Christopher S</ForeName>
                <Initials>CS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Anderson</LastName>
                <ForeName>Garnet</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Anton-Culver</LastName>
                <ForeName>Hoda</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Assimes</LastName>
                <ForeName>Themistocles L</ForeName>
                <Initials>TL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Auer</LastName>
                <ForeName>Paul L</ForeName>
                <Initials>PL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Beresford</LastName>
                <ForeName>Shirley</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bizon</LastName>
                <ForeName>Chris</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Black</LastName>
                <ForeName>Henry</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brunner</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brzyski</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burwen</LastName>
                <ForeName>Dale</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Caan</LastName>
                <ForeName>Bette</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carty</LastName>
                <ForeName>Cara L</ForeName>
                <Initials>CL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chlebowski</LastName>
                <ForeName>Rowan</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cummings</LastName>
                <ForeName>Steven</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Curb</LastName>
                <ForeName>J David</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eaton</LastName>
                <ForeName>Charles B</ForeName>
                <Initials>CB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ford</LastName>
                <ForeName>Leslie</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Franceschini</LastName>
                <ForeName>Nora</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fullerton</LastName>
                <ForeName>Stephanie M</ForeName>
                <Initials>SM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gass</LastName>
                <ForeName>Margery</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Geller</LastName>
                <ForeName>Nancy</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heiss</LastName>
                <ForeName>Gerardo</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Howard</LastName>
                <ForeName>Barbara V</ForeName>
                <Initials>BV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hsu</LastName>
                <ForeName>Li</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hutter</LastName>
                <ForeName>Carolyn M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ioannidis</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jiao</LastName>
                <ForeName>Shuo</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Johnson</LastName>
                <ForeName>Karen C</ForeName>
                <Initials>KC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kooperberg</LastName>
                <ForeName>Charles</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuller</LastName>
                <ForeName>Lewis</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>LaCroix</LastName>
                <ForeName>Andrea</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lakshminarayan</LastName>
                <ForeName>Kamakshi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lane</LastName>
                <ForeName>Dorothy</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Ethan M</ForeName>
                <Initials>EM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Leslie A</ForeName>
                <Initials>LA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lasser</LastName>
                <ForeName>Norman</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>LeBlanc</LastName>
                <ForeName>Erin</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lewis</LastName>
                <ForeName>Cora E</ForeName>
                <Initials>CE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Kuo-Ping</ForeName>
                <Initials>KP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Limacher</LastName>
                <ForeName>Marian</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Dan-Yu</ForeName>
                <Initials>DY</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Logsdon</LastName>
                <ForeName>Benjamin A</ForeName>
                <Initials>BA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ludlam</LastName>
                <ForeName>Shari</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manson</LastName>
                <ForeName>JoAnn E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Margolis</LastName>
                <ForeName>Karen</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martin</LastName>
                <ForeName>Lisa</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McGowan</LastName>
                <ForeName>Joan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Monda</LastName>
                <ForeName>Keri L</ForeName>
                <Initials>KL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kotchen</LastName>
                <ForeName>Jane Morley</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nathan</LastName>
                <ForeName>Lauren</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ockene</LastName>
                <ForeName>Judith</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Sullivan</LastName>
                <ForeName>Mary Jo</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Phillips</LastName>
                <ForeName>Lawrence S</ForeName>
                <Initials>LS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prentice</LastName>
                <ForeName>Ross L</ForeName>
                <Initials>RL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reiner</LastName>
                <ForeName>Alexander P</ForeName>
                <Initials>AP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Robbins</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Robinson</LastName>
                <ForeName>Jennifer G</ForeName>
                <Initials>JG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rossouw</LastName>
                <ForeName>Jacques E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sangi-Haghpeykar</LastName>
                <ForeName>Haleh</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sarto</LastName>
                <ForeName>Gloria E</ForeName>
                <Initials>GE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shumaker</LastName>
                <ForeName>Sally</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Simon</LastName>
                <ForeName>Michael S</ForeName>
                <Initials>MS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stefanick</LastName>
                <ForeName>Marcia L</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stein</LastName>
                <ForeName>Evan</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tang</LastName>
                <ForeName>Hua</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taylor</LastName>
                <ForeName>Kira C</ForeName>
                <Initials>KC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thomson</LastName>
                <ForeName>Cynthia A</ForeName>
                <Initials>CA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thornton</LastName>
                <ForeName>Timothy A</ForeName>
                <Initials>TA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Van Horn</LastName>
                <ForeName>Linda</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vitolins</LastName>
                <ForeName>Mara</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wactawski-Wende</LastName>
                <ForeName>Jean</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wallace</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wassertheil-Smoller</LastName>
                <ForeName>Sylvia</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zeng</LastName>
                <ForeName>Donglin</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Applebaum-Bowden</LastName>
                <ForeName>Deborah</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Feolo</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gan</LastName>
                <ForeName>Weiniu</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paltoo</LastName>
                <ForeName>Dina N</ForeName>
                <Initials>DN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rossouw</LastName>
                <ForeName>Jacques E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sholinsky</LastName>
                <ForeName>Phyliss</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sturcke</LastName>
                <ForeName>Anne</ForeName>
                <Initials>A</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2348</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2348</ArticleId>
            <ArticleId IdType="pubmed">22772371</ArticleId>
            <ArticleId IdType="pmc">PMC4033668</ArticleId>
            <ArticleId IdType="mid">NIHMS386390</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11953129</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>05</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0376-2491</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>82</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Jan</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua yi xue za zhi</Title>
                <ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Study on relationship between leukotrienes and exercise-induced asthma].</ArticleTitle>
            <Pagination>
                <MedlinePgn>54-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To explore the relationship between leukotriene (LT) and exercise-induced asthma.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-two non-smoking asthmatic patients with a reproducible fall in FEV(1) after exercise by least 10% and 10 normal patients were enrolled. Urinary levels of leukotriene E4 were measured before and 2 hours after exercise. Twelve subjects received cysteinyl LT receptor antagonist Zafirlukast (Ancolate) 20 mg twice a day for three days. Standardized exercise challenge were performed after 72 hours. End points included (1) area under the percent fall in FEV(1) versus time curve (AUC 0-60 min), (2) time to recovery to within 5% of the pre-exercise baseline FEV(1) value, (3) and maximum percent fall in FEV(1) from pre-exercise baseline.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">To exercise-induced aothma (EIA) group, urinary LTE4 in 2 hours after exercise were higher than that of in before exercise, P &lt; 0.01. Urinary leukotriene E4 concentration before and 2 hours after exercise were higher than normal subjects. Zafirlukast can caused a significant reduction in AUC(0 - 60 min) (Aera under the FEV(1)-time curve for 0 to 60 minutes after exercise); caused a significant reduction in the maximum percent fall in FEV(1); and Zafirlukast resulted in a shorter time to recovery of FEV(1) to preexercise baseline.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There was an increase in urinary LTE4 during the 2 hours after exercise challenge; Zafirlukast can attenuate EIA. The results indicate that there is an important role of leukotriene in the pathogenesis of exercise-induced asthma.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Tieying</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Beijing Hospital, Beijing 100730, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Yanfei</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Hongsheng</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA>
            <NlmUniqueID>7511141</NlmUniqueID>
            <ISSNLinking>0376-2491</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018927">Anti-Asthmatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020024">Leukotriene Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015289">Leukotrienes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018077">Receptors, Leukotriene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014105">Tosyl Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C412375">cysteinyl leukotriene receptor 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C083169">leukotriene D4 receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>107753-78-6</RegistryNumber>
                <NameOfSubstance UI="C062735">zafirlukast</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>75715-89-8</RegistryNumber>
                <NameOfSubstance UI="D017999">Leukotriene E4</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018927">Anti-Asthmatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001250">Asthma, Exercise-Induced</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000517">prevention &amp; control</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020024">Leukotriene Antagonists</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017999">Leukotriene E4</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015289">Leukotrienes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D008565">Membrane Proteins</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D018077">Receptors, Leukotriene</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014105">Tosyl Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11953129</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22772370</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>07</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>09</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>03</Month>
            <Day>10</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>886-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2344</ELocationID>
            <Abstract>
                <AbstractText>Exome sequencing has become a powerful and effective strategy for the discovery of genes underlying Mendelian disorders. However, use of exome sequencing to identify variants associated with complex traits has been more challenging, partly because the sample sizes needed for adequate power may be very large. One strategy to increase efficiency is to sequence individuals who are at both ends of a phenotype distribution (those with extreme phenotypes). Because the frequency of alleles that contribute to the trait are enriched in one or both phenotype extremes, a modest sample size can potentially be used to identify novel candidate genes and/or alleles. As part of the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP), we used an extreme phenotype study design to discover that variants in DCTN4, encoding a dynactin protein, are associated with time to first P. aeruginosa airway infection, chronic P. aeruginosa infection and mucoid P. aeruginosa in individuals with cystic fibrosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Emond</LastName>
                    <ForeName>Mary J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, University of Washington, Seattle, Washington, USA. mbamshad@u.washington.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Louie</LastName>
                    <ForeName>Tin</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Emerson</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mathias</LastName>
                    <ForeName>Rasika A</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Knowles</LastName>
                    <ForeName>Michael R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wright</LastName>
                    <ForeName>Fred A</ForeName>
                    <Initials>FA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rieder</LastName>
                    <ForeName>Mark J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tabor</LastName>
                    <ForeName>Holly K</ForeName>
                    <Initials>HK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nickerson</LastName>
                    <ForeName>Deborah A</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barnes</LastName>
                    <ForeName>Kathleen C</ForeName>
                    <Initials>KC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Lung GO</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gibson</LastName>
                    <ForeName>Ronald L</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bamshad</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>090532</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>5R01 HG004316</GrantID>
                    <Acronym>HG</Acronym>
                    <Agency>NHGRI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>G0701075</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 DK089507</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HL068890</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL-102923</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL-102924</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL-102925</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL-102926</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL-103010</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL102923</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL102924</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL102925</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL102926</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 HL103010</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>07</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>144198-36-7</RegistryNumber>
                <NameOfSubstance UI="C072084">dynactin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Cardiovasc Genet. 2010 Apr;3(2):215-21</RefSource>
                <PMID Version="1">20407100</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2011 Dec 1;184(11):1237-46</RefSource>
                <PMID Version="1">21836133</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 May;43(5):491-8</RefSource>
                <PMID Version="1">21478889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 Jun;43(6):539-46</RefSource>
                <PMID Version="1">21602797</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Genet. 2011 Nov;12(11):745-55</RefSource>
                <PMID Version="1">21946919</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Biol. 2011;12(9):227</RefSource>
                <PMID Version="1">21920052</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Sci. 2012 Jan 15;125(Pt 2):507-15</RefSource>
                <PMID Version="1">22302984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Pulmonol. 2002 Aug;34(2):91-100</RefSource>
                <PMID Version="1">12112774</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2003 Oct 15;168(8):918-51</RefSource>
                <PMID Version="1">14555458</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Pulmonol. 2004 May;37(5):427-32</RefSource>
                <PMID Version="1">15095326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cyst Fibros. 2003 Mar;2(1):29-34</RefSource>
                <PMID Version="1">15463843</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biotechniques. 2004 Oct;37(4):662-4</RefSource>
                <PMID Version="1">15517978</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2005 Feb 2;293(5):581-8</RefSource>
                <PMID Version="1">15687313</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Respir J. 2006 May;27(5):937-43</RefSource>
                <PMID Version="1">16707392</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Struct Funct. 2008;33(1):109-22</RefSource>
                <PMID Version="1">18388399</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Jul 15;25(14):1754-60</RefSource>
                <PMID Version="1">19451168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Contemp Clin Trials. 2009 May;30(3):256-68</RefSource>
                <PMID Version="1">19470318</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genet Epidemiol. 2010 Feb;34(2):188-93</RefSource>
                <PMID Version="1">19810025</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Respir Res. 2010;11:140</RefSource>
                <PMID Version="1">20932301</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017668">Age of Onset</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003550">Cystic Fibrosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059472">Exome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005787">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015810">Linkage Disequilibrium</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008869">Microtubule-Associated Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010641">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011552">Pseudomonas Infections</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011550">Pseudomonas aeruginosa</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS384651</OtherID>
        <OtherID Source="NLM">PMC3702264</OtherID>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Gabriel</LastName>
                <ForeName>Stacey B</ForeName>
                <Initials>SB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Altshuler</LastName>
                <ForeName>David M</ForeName>
                <Initials>DM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abecasis</LastName>
                <ForeName>Gonçalo R</ForeName>
                <Initials>GR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Allayee</LastName>
                <ForeName>Hooman</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cresci</LastName>
                <ForeName>Sharon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Daly</LastName>
                <ForeName>Mark J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>de Bakker</LastName>
                <ForeName>Paul I W</ForeName>
                <Initials>PI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>DePristo</LastName>
                <ForeName>Mark A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Do</LastName>
                <ForeName>Ron</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Donnelly</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Farlow</LastName>
                <ForeName>Deborah N</ForeName>
                <Initials>DN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fennell</LastName>
                <ForeName>Tim</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Garimella</LastName>
                <ForeName>Kiran</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hazen</LastName>
                <ForeName>Stanley L</ForeName>
                <Initials>SL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hu</LastName>
                <ForeName>Youna</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jordan</LastName>
                <ForeName>Daniel M</ForeName>
                <Initials>DM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jun</LastName>
                <ForeName>Goo</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kathiresan</LastName>
                <ForeName>Sekar</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kang</LastName>
                <ForeName>Hyun Min</ForeName>
                <Initials>HM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kiezun</LastName>
                <ForeName>Adam</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lettre</LastName>
                <ForeName>Guillaume</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Bingshan</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Mingyao</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Newton-Cheh</LastName>
                <ForeName>Christopher H</ForeName>
                <Initials>CH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Padmanabhan</LastName>
                <ForeName>Sandosh</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peloso</LastName>
                <ForeName>Gina</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pulit</LastName>
                <ForeName>Sara</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rader</LastName>
                <ForeName>Daniel J</ForeName>
                <Initials>DJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reich</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reilly</LastName>
                <ForeName>Muredach P</ForeName>
                <Initials>MP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rivas</LastName>
                <ForeName>Manuel A</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schwartz</LastName>
                <ForeName>Steve</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Scott</LastName>
                <ForeName>Laura</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siscovick</LastName>
                <ForeName>David S</ForeName>
                <Initials>DS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spertus</LastName>
                <ForeName>John A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stitziel</LastName>
                <ForeName>Nathaniel O</ForeName>
                <Initials>NO</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stoletzki</LastName>
                <ForeName>Nina</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sunyaev</LastName>
                <ForeName>Shamil R</ForeName>
                <Initials>SR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Voight</LastName>
                <ForeName>Benjamin F</ForeName>
                <Initials>BF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Willer</LastName>
                <ForeName>Cristen J</ForeName>
                <Initials>CJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rich</LastName>
                <ForeName>Stephen S</ForeName>
                <Initials>SS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Akylbekova</LastName>
                <ForeName>Ermeg</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Atwood</LastName>
                <ForeName>Larry D</ForeName>
                <Initials>LD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ballantyne</LastName>
                <ForeName>Christie M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barbalic</LastName>
                <ForeName>Maja</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barr</LastName>
                <ForeName>R Graham</ForeName>
                <Initials>RG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Benjamin</LastName>
                <ForeName>Emelia J</ForeName>
                <Initials>EJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bis</LastName>
                <ForeName>Joshua</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Boerwinkle</LastName>
                <ForeName>Eric</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bowden</LastName>
                <ForeName>Donald W</ForeName>
                <Initials>DW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brody</LastName>
                <ForeName>Jennifer</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Budoff</LastName>
                <ForeName>Matthew</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burke</LastName>
                <ForeName>Greg</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Buxbaum</LastName>
                <ForeName>Sarah</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carr</LastName>
                <ForeName>Jeff</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chen</LastName>
                <ForeName>Donna T</ForeName>
                <Initials>DT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chen</LastName>
                <ForeName>Ida Y</ForeName>
                <Initials>IY</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chen</LastName>
                <ForeName>Wei-Min</ForeName>
                <Initials>WM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Concannon</LastName>
                <ForeName>Pat</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crosby</LastName>
                <ForeName>Jacy</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cupples</LastName>
                <ForeName>L Adrienne</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>D'Agostino</LastName>
                <ForeName>Ralph</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>DeStefano</LastName>
                <ForeName>Anita L</ForeName>
                <Initials>AL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dreisbach</LastName>
                <ForeName>Albert</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dupuis</LastName>
                <ForeName>Josée</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Durda</LastName>
                <ForeName>J Peter</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ellis</LastName>
                <ForeName>Jaclyn</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Folsom</LastName>
                <ForeName>Aaron R</ForeName>
                <Initials>AR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fornage</LastName>
                <ForeName>Myriam</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fox</LastName>
                <ForeName>Caroline S</ForeName>
                <Initials>CS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fox</LastName>
                <ForeName>Ervin</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Funari</LastName>
                <ForeName>Vincent</ForeName>
                <Initials>V</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ganesh</LastName>
                <ForeName>Santhi K</ForeName>
                <Initials>SK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gardin</LastName>
                <ForeName>Julius</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goff</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon</LastName>
                <ForeName>Ora</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Grody</LastName>
                <ForeName>Wayne</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gross</LastName>
                <ForeName>Myron</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Guo</LastName>
                <ForeName>Xiuqing</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hall</LastName>
                <ForeName>Ira M</ForeName>
                <Initials>IM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heard-Costa</LastName>
                <ForeName>Nancy L</ForeName>
                <Initials>NL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heckbert</LastName>
                <ForeName>Susan R</ForeName>
                <Initials>SR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heintz</LastName>
                <ForeName>Nicholas</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Herrington</LastName>
                <ForeName>David M</ForeName>
                <Initials>DM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hickson</LastName>
                <ForeName>DeMarc</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Huang</LastName>
                <ForeName>Jie</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hwang</LastName>
                <ForeName>Shih-Jen</ForeName>
                <Initials>SJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jacobs</LastName>
                <ForeName>David R</ForeName>
                <Initials>DR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jenny</LastName>
                <ForeName>Nancy S</ForeName>
                <Initials>NS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Johnson</LastName>
                <ForeName>Andrew D</ForeName>
                <Initials>AD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Johnson</LastName>
                <ForeName>Craig W</ForeName>
                <Initials>CW</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kawut</LastName>
                <ForeName>Steven</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kronmal</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kurz</LastName>
                <ForeName>Raluca</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Ethan M</ForeName>
                <Initials>EM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Leslie A</ForeName>
                <Initials>LA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Larson</LastName>
                <ForeName>Martin G</ForeName>
                <Initials>MG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lawson</LastName>
                <ForeName>Mark</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lewis</LastName>
                <ForeName>Cora E</ForeName>
                <Initials>CE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Levy</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Dalin</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Honghuang</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Chunyu</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Jiankang</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Kiang</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Xiaoming</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Yongmei</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Longstreth</LastName>
                <ForeName>William T</ForeName>
                <Initials>WT</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Loria</LastName>
                <ForeName>Cay</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lumley</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lunetta</LastName>
                <ForeName>Kathryn</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mackey</LastName>
                <ForeName>Aaron J</ForeName>
                <Initials>AJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mackey</LastName>
                <ForeName>Rachel</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manichaikul</LastName>
                <ForeName>Ani</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maxwell</LastName>
                <ForeName>Taylor</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McKnight</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meigs</LastName>
                <ForeName>James B</ForeName>
                <Initials>JB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morrison</LastName>
                <ForeName>Alanna C</ForeName>
                <Initials>AC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Musani</LastName>
                <ForeName>Solomon K</ForeName>
                <Initials>SK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mychaleckyj</LastName>
                <ForeName>Josyf C</ForeName>
                <Initials>JC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nettleton</LastName>
                <ForeName>Jennifer A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>North</LastName>
                <ForeName>Kari</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Donnell</LastName>
                <ForeName>Christopher J</ForeName>
                <Initials>CJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Leary</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ong</LastName>
                <ForeName>Frank</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Palmas</LastName>
                <ForeName>Walter</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pankow</LastName>
                <ForeName>James S</ForeName>
                <Initials>JS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pankratz</LastName>
                <ForeName>Nathan D</ForeName>
                <Initials>ND</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paul</LastName>
                <ForeName>Shom</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perez</LastName>
                <ForeName>Marco</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Person</LastName>
                <ForeName>Sharina D</ForeName>
                <Initials>SD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Polak</LastName>
                <ForeName>Joseph</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Post</LastName>
                <ForeName>Wendy S</ForeName>
                <Initials>WS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Psaty</LastName>
                <ForeName>Bruce M</ForeName>
                <Initials>BM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Quinlan</LastName>
                <ForeName>Aaron R</ForeName>
                <Initials>AR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Raffel</LastName>
                <ForeName>Leslie J</ForeName>
                <Initials>LJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ramachandran</LastName>
                <ForeName>Vasan S</ForeName>
                <Initials>VS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reiner</LastName>
                <ForeName>Alexander P</ForeName>
                <Initials>AP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rice</LastName>
                <ForeName>Kenneth</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rotter</LastName>
                <ForeName>Jerome I</ForeName>
                <Initials>JI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sanders</LastName>
                <ForeName>Jill P</ForeName>
                <Initials>JP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schreiner</LastName>
                <ForeName>Pamela</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Seshadri</LastName>
                <ForeName>Sudha</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shea</LastName>
                <ForeName>Steve</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sidney</LastName>
                <ForeName>Stephen</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Silverstein</LastName>
                <ForeName>Kevin</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Siscovick</LastName>
                <ForeName>David S</ForeName>
                <Initials>DS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Smith</LastName>
                <ForeName>Nicholas L</ForeName>
                <Initials>NL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sotoodehnia</LastName>
                <ForeName>Nona</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Srinivasan</LastName>
                <ForeName>Asoke</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taylor</LastName>
                <ForeName>Herman A</ForeName>
                <Initials>HA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taylor</LastName>
                <ForeName>Kent</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thomas</LastName>
                <ForeName>Fridtjof</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tracy</LastName>
                <ForeName>Russell P</ForeName>
                <Initials>RP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tsai</LastName>
                <ForeName>Michael Y</ForeName>
                <Initials>MY</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Volcik</LastName>
                <ForeName>Kelly A</ForeName>
                <Initials>KA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wassel</LastName>
                <ForeName>Chrstina L</ForeName>
                <Initials>CL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Watson</LastName>
                <ForeName>Karol</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wei</LastName>
                <ForeName>Gina</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>White</LastName>
                <ForeName>Wendy</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wiggins</LastName>
                <ForeName>Kerri L</ForeName>
                <Initials>KL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilk</LastName>
                <ForeName>Jemma B</ForeName>
                <Initials>JB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Williams</LastName>
                <ForeName>O Dale</ForeName>
                <Initials>O</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilson</LastName>
                <ForeName>Gregory</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wilson</LastName>
                <ForeName>James G</ForeName>
                <Initials>JG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wolf</LastName>
                <ForeName>Phillip</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zakai</LastName>
                <ForeName>Neil A</ForeName>
                <Initials>NA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hardy</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meschia</LastName>
                <ForeName>James F</ForeName>
                <Initials>JF</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nalls</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rich</LastName>
                <ForeName>Stephen S</ForeName>
                <Initials>SS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Singleton</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Worrall</LastName>
                <ForeName>Brad</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bamshad</LastName>
                <ForeName>Michael J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Barnes</LastName>
                <ForeName>Kathleen C</ForeName>
                <Initials>KC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abdulhamid</LastName>
                <ForeName>Ibrahim</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Accurso</LastName>
                <ForeName>Frank</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Beaty</LastName>
                <ForeName>Terri</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bigham</LastName>
                <ForeName>Abigail</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Black</LastName>
                <ForeName>Phillip</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bleecker</LastName>
                <ForeName>Eugene</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Buckingham</LastName>
                <ForeName>Kati</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cairns</LastName>
                <ForeName>Anne Marie</ForeName>
                <Initials>AM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chen</LastName>
                <ForeName>Wei-Min</ForeName>
                <Initials>WM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Caplan</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chatfield</LastName>
                <ForeName>Barbara</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chidekel</LastName>
                <ForeName>Aaron</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cho</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Christiani</LastName>
                <ForeName>David C</ForeName>
                <Initials>DC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crapo</LastName>
                <ForeName>James D</ForeName>
                <Initials>JD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crouch</LastName>
                <ForeName>Julia</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Daley</LastName>
                <ForeName>Denise</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dang</LastName>
                <ForeName>Anthony</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dang</LastName>
                <ForeName>Hong</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>De Paula</LastName>
                <ForeName>Alicia</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>DeCelie-Germana</LastName>
                <ForeName>Joan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dozor</LastName>
                <ForeName>Allen</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Drumm</LastName>
                <ForeName>Mitch</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dyson</LastName>
                <ForeName>Maynard</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Emerson</LastName>
                <ForeName>Julia</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Emond</LastName>
                <ForeName>Mary J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ferkol</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fink</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Foster</LastName>
                <ForeName>Cassandra</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Froh</LastName>
                <ForeName>Deborah</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gao</LastName>
                <ForeName>Li</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gershan</LastName>
                <ForeName>William</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gibson</LastName>
                <ForeName>Ronald L</ForeName>
                <Initials>RL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Godwin</LastName>
                <ForeName>Elizabeth</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gondor</LastName>
                <ForeName>Magdalen</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gutierrez</LastName>
                <ForeName>Hector</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hansel</LastName>
                <ForeName>Nadia N</ForeName>
                <Initials>NN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hassoun</LastName>
                <ForeName>Paul M</ForeName>
                <Initials>PM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hiatt</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hokanson</LastName>
                <ForeName>John E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Howenstine</LastName>
                <ForeName>Michelle</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hummer</LastName>
                <ForeName>Laura K</ForeName>
                <Initials>LK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kanga</LastName>
                <ForeName>Jamshed</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kim</LastName>
                <ForeName>Yoonhee</ForeName>
                <Initials>Y</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Knowles</LastName>
                <ForeName>Michael R</ForeName>
                <Initials>MR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Konstan</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lahiri</LastName>
                <ForeName>Thomas</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Laird</LastName>
                <ForeName>Nan</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Christoph</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Lin</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Xihong</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Louie</LastName>
                <ForeName>Tin L</ForeName>
                <Initials>TL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lynch</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Make</LastName>
                <ForeName>Barry</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martin</LastName>
                <ForeName>Thomas R</ForeName>
                <Initials>TR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathai</LastName>
                <ForeName>Steve C</ForeName>
                <Initials>SC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mathias</LastName>
                <ForeName>Rasika A</ForeName>
                <Initials>RA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McNamara</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McNamara</LastName>
                <ForeName>Sharon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meyers</LastName>
                <ForeName>Deborah</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Millard</LastName>
                <ForeName>Susan</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mogayzel</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Moss</LastName>
                <ForeName>Richard</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Murray</LastName>
                <ForeName>Tanda</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nielson</LastName>
                <ForeName>Dennis</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Noyes</LastName>
                <ForeName>Blakeslee</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Neal</LastName>
                <ForeName>Wanda</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Orenstein</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Sullivan</LastName>
                <ForeName>Brian</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pace</LastName>
                <ForeName>Rhonda</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pare</LastName>
                <ForeName>Peter</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Parker</LastName>
                <ForeName>H Worth</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Passero</LastName>
                <ForeName>Mary Ann</ForeName>
                <Initials>MA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perkett</LastName>
                <ForeName>Elizabeth</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prestridge</LastName>
                <ForeName>Adrienne</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rafaels</LastName>
                <ForeName>Nicholas M</ForeName>
                <Initials>NM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ramsey</LastName>
                <ForeName>Bonnie</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Regan</LastName>
                <ForeName>Elizabeth</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ren</LastName>
                <ForeName>Clement</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Retsch-Bogart</LastName>
                <ForeName>George</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rock</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosen</LastName>
                <ForeName>Antony</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosenfeld</LastName>
                <ForeName>Margaret</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruczinski</LastName>
                <ForeName>Ingo</ForeName>
                <Initials>I</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sanford</LastName>
                <ForeName>Andrew</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schaeffer</LastName>
                <ForeName>David</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sell</LastName>
                <ForeName>Cindy</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sheehan</LastName>
                <ForeName>Daniel</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Silverman</LastName>
                <ForeName>Edwin K</ForeName>
                <Initials>EK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sin</LastName>
                <ForeName>Don</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spencer</LastName>
                <ForeName>Terry</ForeName>
                <Initials>T</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stonebraker</LastName>
                <ForeName>Jackie</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tabor</LastName>
                <ForeName>Holly K</ForeName>
                <Initials>HK</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Varlotta</LastName>
                <ForeName>Laurie</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vergara</LastName>
                <ForeName>Candelaria I</ForeName>
                <Initials>CI</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Weiss</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wigley</LastName>
                <ForeName>Fred</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wise</LastName>
                <ForeName>Robert A</ForeName>
                <Initials>RA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wright</LastName>
                <ForeName>Fred A</ForeName>
                <Initials>FA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wurfel</LastName>
                <ForeName>Mark M</ForeName>
                <Initials>MM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zanni</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zou</LastName>
                <ForeName>Fei</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nickerson</LastName>
                <ForeName>Deborah A</ForeName>
                <Initials>DA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rieder</LastName>
                <ForeName>Mark J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Green</LastName>
                <ForeName>Phil</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shendure</LastName>
                <ForeName>Jay</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Akey</LastName>
                <ForeName>Joshua M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bamshad</LastName>
                <ForeName>Michael J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bustamante</LastName>
                <ForeName>Carlos D</ForeName>
                <Initials>CD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Crosslin</LastName>
                <ForeName>David R</ForeName>
                <Initials>DR</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eichler</LastName>
                <ForeName>Evan E</ForeName>
                <Initials>EE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fox</LastName>
                <ForeName>P Keolu</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fu</LastName>
                <ForeName>Wenqing</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gordon</LastName>
                <ForeName>Adam</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gravel</LastName>
                <ForeName>Simon</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jarvik</LastName>
                <ForeName>Gail P</ForeName>
                <Initials>GP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Johnsen</LastName>
                <ForeName>Jill M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kan</LastName>
                <ForeName>Mengyuan</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kenny</LastName>
                <ForeName>Eimear E</ForeName>
                <Initials>EE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kidd</LastName>
                <ForeName>Jeffrey M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lara-Garduno</LastName>
                <ForeName>Fremiet</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leal</LastName>
                <ForeName>Suzanne M</ForeName>
                <Initials>SM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Liu</LastName>
                <ForeName>Dajiang J</ForeName>
                <Initials>DJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McGee</LastName>
                <ForeName>Sean</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Connor</LastName>
                <ForeName>Timothy D</ForeName>
                <Initials>TD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paeper</LastName>
                <ForeName>Bryan</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Robertson</LastName>
                <ForeName>Peggy D</ForeName>
                <Initials>PD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Smith</LastName>
                <ForeName>Joshua D</ForeName>
                <Initials>JD</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Staples</LastName>
                <ForeName>Jeffrey C</ForeName>
                <Initials>JC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tennessen</LastName>
                <ForeName>Jacob A</ForeName>
                <Initials>JA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Turner</LastName>
                <ForeName>Emily H</ForeName>
                <Initials>EH</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wang</LastName>
                <ForeName>Gao</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Yi</LastName>
                <ForeName>Qian</ForeName>
                <Initials>Q</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jackson</LastName>
                <ForeName>Rebecca</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>North</LastName>
                <ForeName>Kari</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peters</LastName>
                <ForeName>Ulrike</ForeName>
                <Initials>U</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carlson</LastName>
                <ForeName>Christopher S</ForeName>
                <Initials>CS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Anderson</LastName>
                <ForeName>Garnet</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoda</LastName>
                <ForeName>Anton- Culver</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Assimes</LastName>
                <ForeName>Themistocles L</ForeName>
                <Initials>TL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Auer</LastName>
                <ForeName>Paul L</ForeName>
                <Initials>PL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Beresford</LastName>
                <ForeName>Shirley</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bizon</LastName>
                <ForeName>Chris</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Black</LastName>
                <ForeName>Henry</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brunner</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brzyski</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burwen</LastName>
                <ForeName>Dale</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Caan</LastName>
                <ForeName>Bette</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Carty</LastName>
                <ForeName>Cara L</ForeName>
                <Initials>CL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chlebowski</LastName>
                <ForeName>Rowan</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cummings</LastName>
                <ForeName>Steven</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Curb</LastName>
                <ForeName>J David</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Eaton</LastName>
                <ForeName>Charles B</ForeName>
                <Initials>CB</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ford</LastName>
                <ForeName>Leslie</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Franceschini</LastName>
                <ForeName>Nora</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fullerton</LastName>
                <ForeName>Stephanie M</ForeName>
                <Initials>SM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gass</LastName>
                <ForeName>Margery</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Geller</LastName>
                <ForeName>Nancy</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Heiss</LastName>
                <ForeName>Gerardo</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Howard</LastName>
                <ForeName>Barbara V</ForeName>
                <Initials>BV</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hsu</LastName>
                <ForeName>Li</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hutter</LastName>
                <ForeName>Carolyn M</ForeName>
                <Initials>CM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ioannidis</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jiao</LastName>
                <ForeName>Shuo</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Johnson</LastName>
                <ForeName>Karen C</ForeName>
                <Initials>KC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kooperberg</LastName>
                <ForeName>Charles</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kuller</LastName>
                <ForeName>Lewis</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>LaCroix</LastName>
                <ForeName>Andrea</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lakshminarayan</LastName>
                <ForeName>Kamakshi</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lane</LastName>
                <ForeName>Dorothy</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Ethan M</ForeName>
                <Initials>EM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lange</LastName>
                <ForeName>Leslie A</ForeName>
                <Initials>LA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lasser</LastName>
                <ForeName>Norman</ForeName>
                <Initials>N</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>LeBlanc</LastName>
                <ForeName>Erin</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lewis</LastName>
                <ForeName>Cora E</ForeName>
                <Initials>CE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Li</LastName>
                <ForeName>Kuo-Ping</ForeName>
                <Initials>KP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Limacher</LastName>
                <ForeName>Marian</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lin</LastName>
                <ForeName>Dan-Yu</ForeName>
                <Initials>DY</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Logsdon</LastName>
                <ForeName>Benjamin A</ForeName>
                <Initials>BA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ludlam</LastName>
                <ForeName>Shari</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Manson</LastName>
                <ForeName>JoAnn E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Margolis</LastName>
                <ForeName>Karen</ForeName>
                <Initials>K</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Martin</LastName>
                <ForeName>Lisa</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>McGowan</LastName>
                <ForeName>Joan</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Monda</LastName>
                <ForeName>Keri L</ForeName>
                <Initials>KL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Kotchen</LastName>
                <ForeName>Jane Morley</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nathan</LastName>
                <ForeName>Lauren</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ockene</LastName>
                <ForeName>Judith</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>O'Sullivan</LastName>
                <ForeName>Mary Jo</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Phillips</LastName>
                <ForeName>Lawrence S</ForeName>
                <Initials>LS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Prentice</LastName>
                <ForeName>Ross L</ForeName>
                <Initials>RL</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Reiner</LastName>
                <ForeName>Alexander P</ForeName>
                <Initials>AP</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Robbins</LastName>
                <ForeName>John</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Robinson</LastName>
                <ForeName>Jennifer G</ForeName>
                <Initials>JG</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rossouw</LastName>
                <ForeName>Jacques E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sangi-Haghpeykar</LastName>
                <ForeName>Haleh</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sarto</LastName>
                <ForeName>Gloria E</ForeName>
                <Initials>GE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Shumaker</LastName>
                <ForeName>Sally</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Simon</LastName>
                <ForeName>Michael S</ForeName>
                <Initials>MS</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stefanick</LastName>
                <ForeName>Marcia L</ForeName>
                <Initials>ML</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Stein</LastName>
                <ForeName>Evan</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tang</LastName>
                <ForeName>Hua</ForeName>
                <Initials>H</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taylor</LastName>
                <ForeName>Kira C</ForeName>
                <Initials>KC</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thomson</LastName>
                <ForeName>Cynthia A</ForeName>
                <Initials>CA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Thornton</LastName>
                <ForeName>Timothy A</ForeName>
                <Initials>TA</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Van Horn</LastName>
                <ForeName>Linda</ForeName>
                <Initials>L</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vitolins</LastName>
                <ForeName>Mara</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wactawski-Wende</LastName>
                <ForeName>Jean</ForeName>
                <Initials>J</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wallace</LastName>
                <ForeName>Robert</ForeName>
                <Initials>R</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Wassertheil-Smoller</LastName>
                <ForeName>Sylvia</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zeng</LastName>
                <ForeName>Donglin</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Applebaum-Bowden</LastName>
                <ForeName>Deborah</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Feolo</LastName>
                <ForeName>Michael</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gan</LastName>
                <ForeName>Weiniu</ForeName>
                <Initials>W</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Paltoo</LastName>
                <ForeName>Dina N</ForeName>
                <Initials>DN</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rossouw</LastName>
                <ForeName>Jacques E</ForeName>
                <Initials>JE</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sholinsky</LastName>
                <ForeName>Phyliss</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sturcke</LastName>
                <ForeName>Anne</ForeName>
                <Initials>A</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2012</Year>
                <Month>3</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>6</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>10</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2344</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2344</ArticleId>
            <ArticleId IdType="pubmed">22772370</ArticleId>
            <ArticleId IdType="pmc">PMC3702264</ArticleId>
            <ArticleId IdType="mid">NIHMS384651</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18541676</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>06</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>07</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1535-2900</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>65</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Jun</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</Title>
                <ISOAbbreviation>Am J Health Syst Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pulmonary arterial hypertension seen in methamphetamine abusers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1109-10</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2146/news080049</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Thompson</LastName>
                    <ForeName>Cheryl A</ForeName>
                    <Initials>CA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016433">News</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Health Syst Pharm</MedlineTA>
            <NlmUniqueID>9503023</NlmUniqueID>
            <ISSNLinking>1079-2082</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>44RAL3456C</RegistryNumber>
                <NameOfSubstance UI="D008694">Methamphetamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019969">Amphetamine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000697">Central Nervous System Stimulants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006976">Hypertension, Pulmonary</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008694">Methamphetamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>7</Month>
                <Day>25</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>6</Month>
                <Day>11</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">65/12/1109</ArticleId>
            <ArticleId IdType="doi">10.2146/news080049</ArticleId>
            <ArticleId IdType="pubmed">18541676</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17697554</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>08</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>03</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <JournalIssue CitedMedium="Print">
                    <Volume>26</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Ai zheng = Aizheng = Chinese journal of cancer</Title>
                <ISOAbbreviation>Ai Zheng</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].</ArticleTitle>
            <Pagination>
                <MedlinePgn>890-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; OBJECTIVE" NlmCategory="OBJECTIVE">Advanced pancreatic cancer has a poor prognosis. Gemcitabine (GEM) can improve the quality of life of pancreatic cancer patients. However, the efficacy of gemcitabine-based combination chemotherapy is uncertain. This study was to compare the efficacy of GEM-based combination therapy and GEM alone on advanced pancreatic cancer.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Clinical data of 40 patients with pathologically or clinically diagnosed advanced pancreatic cancer were analyzed. Of the 40 patients, 15 were treated with GEM (1,000 mg/m(2)) alone weekly for 7 weeks followed by a 2-week rest, then received cycles of 3-week administration with 1-week rest; 25 were treated with GEM (1,000 mg/m(2)) weekly for 2 weeks plus 5-fluorouracil (5-FU) (425-600 mg/m(2)) as bolus at Day 1-5 or 120-hour infusion every 21 days, or cisplatin (DDP) (30-37.5 mg/m(2)) at Day 1-2 every 21 days, or oxaliplatin (85-130 mg/m(2)) at Day 1 every 21 days, or capecitabine (1,000 mg/m(2)) twice a day at Day 1-14 every 21 days, respectively. The survival was analyzed by Kaplan-Meier method. Median time to progression (mTTP), clinical benefit response (CBR), disease control rate, median overall survival (mOS) and toxicity were assessed according to World Health Organization criteria.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The rate of CBR was 56.0% in GEM-combination group and 46.7% in GEM alone group. There were no significant differences in disease control rate, mOS, CBR, and adverse events between the two groups (all P&gt;0.05). However, for the patients with stage III-IV advanced pancreatic cancer, the disease control rate was higher in GEM-combination group than in GEM alone group (75.0% vs. 45.5%, P=0.13).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">GEM-combination regimens and GEM alone have similar efficacy, and lead to similar clinical benefit response and mOS for the patients with advanced pancreatic cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Ji-Fang</ForeName>
                    <Initials>JF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Digestive Disease, School of Oncology &amp; Beijing Cancer Hospital, Peking University, Beijing, 100036, PR China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiao-Dong</ForeName>
                    <Initials>XD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Di</LastName>
                    <ForeName>Li-Jun</ForeName>
                    <Initials>LJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jin</LastName>
                    <ForeName>Mao-Lin</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Lin</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Ai Zheng</MedlineTA>
            <NlmUniqueID>9424852</NlmUniqueID>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>04ZR38536J</RegistryNumber>
                <NameOfSubstance UI="C030110">oxaliplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0W860991D6</RegistryNumber>
                <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6804DJ8Z9U</RegistryNumber>
                <NameOfSubstance UI="C110904">capecitabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B76N6SBZ8R</RegistryNumber>
                <NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q20Q21Q62J</RegistryNumber>
                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000230">Adenocarcinoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000740">Anemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000964">Antimetabolites, Antineoplastic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007970">Leukopenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009944">Organoplatinum Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010190">Pancreatic Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012074">Remission Induction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1000-467X200708890</ArticleId>
            <ArticleId IdType="pubmed">17697554</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2895987</PMID>
        <DateCreated>
            <Year>1988</Year>
            <Month>05</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1988</Year>
            <Month>05</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-953X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>145</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1988</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of psychiatry</Title>
                <ISOAbbreviation>Am J Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder.</ArticleTitle>
            <Pagination>
                <MedlinePgn>621-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A variety of side effects developed in children treated with neuroleptics for Tourette's disorder. Of 208 children, 34 manifested dose-related symptoms of dysphoria, nine experienced a worsening of symptoms of Tourette's disorder that was attributed to akathisia, five became hostile and aggressive, three developed &quot;fog states&quot; that disappeared with discontinuation of neuroleptics or treatment with primidone, and three experienced symptoms of tardive dyskinesia that resolved with time. This data base of neuroleptic-treated children with Tourette's disorder demonstrates a variety of subtle and underrecognized side effects that may not be as readily discernible in children receiving neuroleptics for a primary psychiatric disorder.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bruun</LastName>
                    <ForeName>R D</ForeName>
                    <Initials>RD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Cornell University Medical School, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Psychiatry</MedlineTA>
            <NlmUniqueID>0370512</NlmUniqueID>
            <ISSNLinking>0002-953X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1HIZ4DL86F</RegistryNumber>
                <NameOfSubstance UI="D010868">Pimozide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J6292F8L3D</RegistryNumber>
                <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000374">Aggression</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017109">Akathisia, Drug-Induced</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006220">Haloperidol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006791">Hostility</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010868">Pimozide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005879">Tourette Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1988</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1988</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1988</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2895987</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17697552</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>08</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>10</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>03</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <JournalIssue CitedMedium="Print">
                    <Volume>26</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Ai zheng = Aizheng = Chinese journal of cancer</Title>
                <ISOAbbreviation>Ai Zheng</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].</ArticleTitle>
            <Pagination>
                <MedlinePgn>880-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND &amp; OBJECTIVE" NlmCategory="OBJECTIVE">Docetaxel and cisplatin (DDP) are effective drugs for head and neck tumors. Stage II-III clinical trial of TP regimen (docetaxel combined DDP) for head and neck tumors has completed. This study was to compare the efficacy and toxicity of TP regimen and PF regimen [DDP combined 5-fluorouracil (5-FU)] in treating nasopharyngeal carcinoma (NPC), to provide a new chemotherapeutic regimen for NPC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Twenty NPC patients treated in Cancer Center of Sun Yat-sen University between Oct. 1, 2005 and Mar. 1, 2006 were subjected to study group (TP group). Twenty patients were chosen randomly from the 45 NPC patients treated with PF regimen between May 1, 2004 and Sep. 30, 2005 as control group (PF group). Both groups received concurrent radiotherapy. The efficacy and adverse events of the 2 groups were compared.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean number of chemotherapy cycles was significantly higher in TP group than in PF group (3.85 cycles vs. 2.75 cycles, P&lt;0.001). After induction chemotherapy, in TP group, 18 achieved partial remission (PR) and 2 had stable disease (SD) for nasopharyngeal lesions, 7 achieved complete remission (CR), 11 achieved PR and 2 had SD for regional lymph nodes; in PF group, 17 achieved PR and 3 had SD for nasopharyngeal lesions, 2 achieved CR, 15 achieved PR and 1 had SD for regional lymph nodes. After concurrent chemoradiotherapy, all in TP group and 18 in PF group achieved CR for nasopharyngeal lesions, and 19 in TP group and 15 in PF group achieved CR for regional lymph nodes. There was no significant difference in efficacy between the 2 groups (P&gt;0.05). The occurrence rates of grade 3-4 neutropenia were significantly higher in TP group than in PF group (40.5% vs. 0% after induction chemotherapy, 40.5% vs. 10.2% after concurrent radiochemotherapy, P&lt;0.05). The occurrence rates of anemia and thrombocytopenia were significantly lower in TP group than in PF group (P&lt;0.05). The uses of antibiotics and parenteral nutritional support in the 2 groups were similar.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The efficacy of TP regimen on NPC is similar to that of PF regimen, and the adverse events are tolerable, but the long-term outcomes and toxicities need to be further investigated.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xie</LastName>
                    <ForeName>Fang-Yun</ForeName>
                    <Initials>FY</Initials>
                    <AffiliationInfo>
                        <Affiliation>State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, PR China. xiefangy@mail.sysu.edu.cn</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Shu-Nan</ForeName>
                    <Initials>SN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Wei-Han</ForeName>
                    <Initials>WH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zou</LastName>
                    <ForeName>Guo-Rong</ForeName>
                    <Initials>GR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peng</LastName>
                    <ForeName>Miao</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Ji-Shi</ForeName>
                    <Initials>JS</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Ai Zheng</MedlineTA>
            <NlmUniqueID>9424852</NlmUniqueID>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>15H5577CQD</RegistryNumber>
                <NameOfSubstance UI="C067311">docetaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q20Q21Q62J</RegistryNumber>
                <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <SupplMeshList>
            <SupplMeshName Type="Protocol" UI="C095424">CF regimen</SupplMeshName>
        </SupplMeshList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000740">Anemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002294">Carcinoma, Squamous Cell</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002945">Cisplatin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007970">Leukopenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008207">Lymphatic Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009303">Nasopharyngeal Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000532">radiotherapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010315">Particle Accelerators</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011882">Radiotherapy, High-Energy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013280">Stomatitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043823">Taxoids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1000-467X200708880</ArticleId>
            <ArticleId IdType="pubmed">17697552</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7393810</PMID>
        <DateCreated>
            <Year>1980</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1980</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0032-5473</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>56</Volume>
                    <Issue>653</Issue>
                    <PubDate>
                        <Year>1980</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Postgraduate medical journal</Title>
                <ISOAbbreviation>Postgrad Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prolonged dystonic reaction to chlorpromazine in myxoedema coma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>192-3</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A case of myxoedema coma is reported where the administration of chlorpromazine resulted in a prolonged dystonic reaction. A similar challenge with a butyrophenone when the patient was on thyroxine caused a similar but much abbreviated response.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wood</LastName>
                    <ForeName>G M</ForeName>
                    <Initials>GM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Waters</LastName>
                    <ForeName>A K</ForeName>
                    <Initials>AK</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Postgrad Med J</MedlineTA>
            <NlmUniqueID>0234135</NlmUniqueID>
            <ISSNLinking>0032-5473</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>U42B7VYA4P</RegistryNumber>
                <NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Schweiz Med Wochenschr. 1969 Jul 26;99(31):1107-9</RefSource>
                <PMID Version="1">5406975</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002746">Chlorpromazine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003128">Coma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009230">Myxedema</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2425851</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1980</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1980</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1980</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7393810</ArticleId>
            <ArticleId IdType="pmc">PMC2425851</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">739613</PMID>
        <DateCreated>
            <Year>1979</Year>
            <Month>04</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1979</Year>
            <Month>04</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0485-1439</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>1978</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>[Rinshō ketsueki] The Japanese journal of clinical hematology</Title>
                <ISOAbbreviation>Rinsho Ketsueki</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[A case of mefenamic acid-induced autoimmune hemolytic anemia (author's transl)].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1575-80</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sakai</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akihama</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miura</LastName>
                    <ForeName>A B</ForeName>
                    <Initials>AB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Komatsu</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shibata</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>jpn</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>JAPAN</Country>
            <MedlineTA>Rinsho Ketsueki</MedlineTA>
            <NlmUniqueID>2984782R</NlmUniqueID>
            <ISSNLinking>0485-1439</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>367589PJ2C</RegistryNumber>
                <NameOfSubstance UI="D008528">Mefenamic Acid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000744">Anemia, Hemolytic, Autoimmune</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008528">Mefenamic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1978</Year>
                <Month>11</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1978</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1978</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">739613</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2665757</PMID>
        <DateCreated>
            <Year>1989</Year>
            <Month>08</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1989</Year>
            <Month>08</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0004-4172</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>39</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Arzneimittel-Forschung</Title>
                <ISOAbbreviation>Arzneimittelforschung</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In vitro cardiac effects and antiarrhythmic properties of guanfacine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>450-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Guanfacine (Estulic, Tenex), a centrally acting antihypertensive, was investigated for its effects on the heart using isolated cardiac preparations and in patients for antiarrhythmic properties. The tachycardic effects of sympathetic nerve stimulation in spontaneously beating atria were concentration-dependently suppressed by guanfacine. A 50% inhibition was observed in atria from Syrian hamsters, guinea-pigs and rabbits with 1, 5.4 and 20 nmol/l, respectively. In guinea-pig atria the concentration-response curve of guanfacine was shifted to the right in a parallel manner by rauwolscine (pA2 8.58) but was not displaced by prazosine 1 mumol/l. In rabbit right papillary muscles guanfacine 1 to 10 mumol/l increased force of contraction by 13 to 91%. The positive inotropic effect was antagonized by prazosine 1 mumol/l but was not influenced by cimetidine 1 mumol/l or rauwolscine 1 mumol/l. It is concluded that guanfacine activates cardiac postsynaptic a1- and neuronal presynaptic a2-adrenoceptors with a preference to the latter of about 2 orders of magnitude. Direct membrane stabilizing effects in guinea-pig atria were negligible. In 4 patients with coronary heart disease associated with arrhythmia guanfacine 1 mg per day during 10 days decreased ventricular premature contractions, couplets and abolished appearance of ventricular tachycardias. These preliminary clinical results indicate that guanfacine may reduce cardiac risk factors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Scholtysik</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Preclinical Research, Sandoz Ltd., Basle, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brugger</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY, WEST</Country>
            <MedlineTA>Arzneimittelforschung</MedlineTA>
            <NlmUniqueID>0372660</NlmUniqueID>
            <ISSNLinking>0004-4172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006146">Guanidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010648">Phenylacetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>30OMY4G3MK</RegistryNumber>
                <NameOfSubstance UI="D016316">Guanfacine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000889">Anti-Arrhythmia Agents</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000959">Antihypertensive Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002462">Cell Membrane</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006224">Cricetinae</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004558">Electric Stimulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016316">Guanfacine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006146">Guanidines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006168">Guinea Pigs</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006321">Heart</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007537">Isometric Contraction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008647">Mesocricetus</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009200">Myocardial Contraction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010210">Papillary Muscles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010648">Phenylacetates</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011817">Rabbits</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012032">Refractory Period, Electrophysiological</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>4</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2665757</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9246051</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0163-2116</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>42</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>1997</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Digestive diseases and sciences</Title>
                <ISOAbbreviation>Dig. Dis. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1486-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The antifungal drug terbinafine has infrequently been incriminated in the occurrence of acute liver injury. We report a case of prolonged cholestasis that occurred in a 75-year-old woman, following terbinafine administration. Jaundice followed by pruritus appeared after four weeks of therapy and was associated with mixed hepatocellular and cholestatic liver tests abnormalities. Following drug withdrawal, serum bilirubin returned to normal values within three months, but anicteric cholestasis persisted for over six months. A liver biopsy performed after six months showed centrilobular cholestasis, discrete portal fibrosis, and a reduction in the number of interlobular biliary ducts. Terbinafine should be added to the list of drugs that can cause reduction in interlobular bile ducts.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mallat</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'Hépatologie et de Gastroentérologie, Hôpital Henri Mondor, Créteil, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zafrani</LastName>
                    <ForeName>E S</ForeName>
                    <Initials>ES</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Metreau</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dhumeaux</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Dig Dis Sci</MedlineTA>
            <NlmUniqueID>7902782</NlmUniqueID>
            <ISSNLinking>0163-2116</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009281">Naphthalenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G7RIW8S0XP</RegistryNumber>
                <NameOfSubstance UI="C041359">terbinafine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000935">Antifungal Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001653">Bile Ducts, Intrahepatic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002179">Candidiasis, Cutaneous</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002780">Cholestasis, Intrahepatic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009281">Naphthalenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1997</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1997</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1997</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9246051</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21277885</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>04</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0333</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>251</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Mar</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Secretory phospholipase A₂-mediated progression of hepatotoxicity initiated by acetaminophen is exacerbated in the absence of hepatic COX-2.</ArticleTitle>
            <Pagination>
                <MedlinePgn>173-80</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2011.01.013</ELocationID>
            <Abstract>
                <AbstractText>We have previously reported that among the other death proteins, hepatic secretory phospholipase A₂ (sPLA₂) is a leading mediator of progression of liver injury initiated by CCl₄ in rats. The aim of our present study was to test the hypothesis that increased hepatic sPLA₂ released after acetaminophen (APAP) challenge mediates progression of liver injury in wild type (WT) and COX-2 knockout (KO) mice. COX-2 WT and KO mice were administered a normally non lethal dose (400 mg/kg) of acetaminophen. The COX-2 KO mice suffered 60% mortality compared to 100% survival of the WT mice, suggesting higher susceptibility of COX-2 KO mice to sPLA₂-mediated progression of acetaminophen hepatotoxicity. Liver injury was significantly higher at later time points in the KO mice compared to the WT mice indicating that the abatement of progression of injury requires the presence of COX-2. This difference in hepatotoxicity was not due to increased bioactivation of acetaminophen as indicated by unchanged cyp2E1 protein and covalently bound ¹⁴C-APAP in the livers of KO mice. Hepatic sPLA₂ activity and plasma TNF-α were significantly higher after APAP administration in the KO mice. This was accompanied by a corresponding fall in hepatic PGE₂ and lower compensatory liver regeneration and repair (³H-thymidine incorporation) in the KO mice. These results suggest that hindered compensatory tissue repair and poor resolution of inflammation for want of beneficial prostaglandins render the liver very vulnerable to sPLA₂-mediated progression of liver injury. These findings are consistent with the destructive role of sPLA₂ in the progression and expansion of tissue injury as a result of continued hydrolytic breakdown of plasma membrane phospholipids of perinecrotic hepatocytes unless mitigated by sufficient co-induction of COX-2.</AbstractText>
                <CopyrightInformation>Copyright © 2011. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bhave</LastName>
                    <ForeName>Vishakha S</ForeName>
                    <Initials>VS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Toxicology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209-0470, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Donthamsetty</LastName>
                    <ForeName>Shashikiran</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Latendresse</LastName>
                    <ForeName>John R</ForeName>
                    <Initials>JR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cunningham</LastName>
                    <ForeName>Michael L</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mehendale</LastName>
                    <ForeName>Harihara M</ForeName>
                    <Initials>HM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>01</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>362O9ITL9D</RegistryNumber>
                <NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.99.1</RegistryNumber>
                <NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.4</RegistryNumber>
                <NameOfSubstance UI="D054497">Phospholipases A2, Secretory</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K7Q1JQR04M</RegistryNumber>
                <NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000082">Acetaminophen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018712">Analgesics, Non-Narcotic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051546">Cyclooxygenase 2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015232">Dinoprostone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008115">Liver Regeneration</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054497">Phospholipases A2, Secretory</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013534">Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014409">Tumor Necrosis Factor-alpha</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>10</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>1</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-008X(11)00023-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2011.01.013</ArticleId>
            <ArticleId IdType="pubmed">21277885</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">7393813</PMID>
        <DateCreated>
            <Year>1980</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1980</Year>
            <Month>09</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0032-5473</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>56</Volume>
                    <Issue>653</Issue>
                    <PubDate>
                        <Year>1980</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Postgraduate medical journal</Title>
                <ISOAbbreviation>Postgrad Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cholestatic jaundice due to co-trimoxazole.</ArticleTitle>
            <Pagination>
                <MedlinePgn>202-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>A patient developed cholestatic jaundice following therapy with co-trimoxazole. Inadvertent re-challenge with the drug resulted in further clinical and biochemical deterioration, but complete recovery ensued on stopping this drug.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ogilvie</LastName>
                    <ForeName>A L</ForeName>
                    <Initials>AL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toghill</LastName>
                    <ForeName>P J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Postgrad Med J</MedlineTA>
            <NlmUniqueID>0234135</NlmUniqueID>
            <ISSNLinking>0032-5473</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AN164J8Y0X</RegistryNumber>
                <NameOfSubstance UI="D014295">Trimethoprim</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JE42381TNV</RegistryNumber>
                <NameOfSubstance UI="D013420">Sulfamethoxazole</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1966 Jan 13;274(2):95-7</RefSource>
                <PMID Version="1">5901208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1966 Jul 7;275(1):39</RefSource>
                <PMID Version="1">4223009</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1967 Oct 12;277(15):785-8</RefSource>
                <PMID Version="1">6046676</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Johns Hopkins Med J. 1970 Mar;126(3):130-3</RefSource>
                <PMID Version="1">5438369</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1973 Jun 4;224(10):1390-2</RefSource>
                <PMID Version="1">4739987</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 1975 Sep 1;233(9):952-3</RefSource>
                <PMID Version="1">1173911</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ugeskr Laeger. 1976 Feb 9;138(7):422-4</RefSource>
                <PMID Version="1">1251524</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002780">Cholestasis, Intrahepatic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004338">Drug Combinations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013420">Sulfamethoxazole</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014295">Trimethoprim</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC2425863</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1980</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1980</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1980</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">7393813</ArticleId>
            <ArticleId IdType="pmc">PMC2425863</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">622432</PMID>
        <DateCreated>
            <Year>1978</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1978</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0033-3182</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1978</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Psychosomatics</Title>
                <ISOAbbreviation>Psychosomatics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Transient aphasia with lithium toxicity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>25-6</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Krakower</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Psychosomatics</MedlineTA>
            <NlmUniqueID>0376506</NlmUniqueID>
            <ISSNLinking>0033-3182</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>9FN79X2M3F</RegistryNumber>
                <NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001037">Aphasia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1978</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1978</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1978</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">622432</ArticleId>
            <ArticleId IdType="pii">S0033-3182(78)71031-5</ArticleId>
            <ArticleId IdType="doi">10.1016/S0033-3182(78)71031-5</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3337520</PMID>
        <DateCreated>
            <Year>1988</Year>
            <Month>02</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1988</Year>
            <Month>02</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0003-4819</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>108</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1988</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of internal medicine</Title>
                <ISOAbbreviation>Ann. Intern. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Amiodarone-induced delirium.</ArticleTitle>
            <Pagination>
                <MedlinePgn>68-9</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Trohman</LastName>
                    <ForeName>R G</ForeName>
                    <Initials>RG</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Miami School of Medicine, Florida.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castellanos</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castellanos</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kessler</LastName>
                    <ForeName>K M</ForeName>
                    <Initials>KM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Ann Intern Med</MedlineTA>
            <NlmUniqueID>0372351</NlmUniqueID>
            <ISSNLinking>0003-4819</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>N3RQ532IUT</RegistryNumber>
                <NameOfSubstance UI="D000638">Amiodarone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000638">Amiodarone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003693">Delirium</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006352">Heart Ventricles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013610">Tachycardia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1988</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1988</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1988</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3337520</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12739036</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>11</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>03</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0172-8172</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>23</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Rheumatology international</Title>
                <ISOAbbreviation>Rheumatol. Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>319-23</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We report the clinical and bioptic findings for a 57-year-old woman with severe chloroquine-induced myopathy. Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide. Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy. Routine controls revealed markedly elevated CK levels of 1,700 U/l. The neurological and electrophysiological findings were not typical of myositis. Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy. As it revealed chloroquine-induced myopathy, medication was stopped. Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Richter</LastName>
                    <ForeName>Jutta G</ForeName>
                    <Initials>JG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Rheumazentrum Düsseldorf, Heinrich-Heine-Universität, Postfach 10 10 07, 40001, Düsseldorf, Germany. richterj@uni-duesseldorf.de</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Becker</LastName>
                    <ForeName>Arnd</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ostendorf</LastName>
                    <ForeName>Benedikt</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Specker</LastName>
                    <ForeName>Christof</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stoll</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neuen-Jacob</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schneider</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2003</Year>
                <Month>05</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Rheumatol Int</MedlineTA>
            <NlmUniqueID>8206885</NlmUniqueID>
            <ISSNLinking>0172-8172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>886U3H6UFF</RegistryNumber>
                <NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.3.2</RegistryNumber>
                <NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018501">Antirheumatic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002738">Chloroquine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003402">Creatine Kinase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008180">Lupus Erythematosus, Systemic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008854">Microscopy, Electron</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009135">Muscular Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009210">Myofibrils</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2002</Year>
                <Month>Oct</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2003</Year>
                <Month>Jan</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2003</Year>
                <Month>May</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12739036</ArticleId>
            <ArticleId IdType="doi">10.1007/s00296-003-0309-0</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19683566</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3169</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>191</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Dec</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology letters</Title>
                <ISOAbbreviation>Toxicol. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lactational fenvalerate exposure permanently impairs testicular development and spermatogenesis in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>47-56</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxlet.2009.08.007</ELocationID>
            <Abstract>
                <AbstractText>Fenvalerate, a widely used synthetic pyrethroid insecticide, has been associated with poor semen quality in human being. However, little is known about the effects of lactational fenvalerate exposure on testicular development and spermatogenesis. The purpose of the present study was to investigate the effects of maternal fenvalerate exposure during lactation on testicular development and spermatogenesis in male offspring. Maternal mice were administered with fenvalerate (60 mg/kg) by gavage daily from postnatal day (PND) 0 to PND21. Lactational fenvalerate exposure markedly decreased the absolute and relative weights of testes and increased the number of apoptotic cells in testes of pups at weaning. Histological examinations showed abnormal seminiferous tubules with large vacuoles or complete spermatogenic failure in testes of fenvalerate-treated mice at weaning. Additional experiment showed that lactational fenvalerate exposure markedly reduced mRNA and protein levels of testicular P450scc, a testosterone (T) synthesis enzyme. Consistent with down-regulation of testicular P450scc, the level of serum and testicular T at weaning was significantly decreased in pups whose mothers were exposed to fenvalerate during lactation. Although the expression of testicular P450scc and serum and testicular T in adulthood restored to control level, the decreased weight of testes and histological changes were irreversible. Importantly, the percentage of mature seminiferous tubules (stages VII and VIII) and the number of spermatozoa were obviously decreased in adult male mice whose mothers were exposed to fenvalerate during lactation. Taken together, these results suggest that lactational fenvalerate exposure permanently impairs testicular development and spermatogenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Heng</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Toxicology, Anhui Medical University, Hefei 230032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ji</LastName>
                    <ForeName>Yan-Li</ForeName>
                    <Initials>YL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ning</LastName>
                    <ForeName>Huan</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Cheng</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Xian-Feng</ForeName>
                    <Initials>XF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Qun</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Meng</LastName>
                    <ForeName>Xiu-Hong</ForeName>
                    <Initials>XH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>De-Xiang</ForeName>
                    <Initials>DX</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Toxicol Lett</MedlineTA>
            <NlmUniqueID>7709027</NlmUniqueID>
            <ISSNLinking>0378-4274</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007306">Insecticides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009570">Nitriles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011722">Pyrethrins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C090395">steroidogenic acute regulatory protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3XMK78S47O</RegistryNumber>
                <NameOfSubstance UI="D013739">Testosterone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Z6MXZ39302</RegistryNumber>
                <NameOfSubstance UI="C017690">fenvalerate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020567">Fetal Weight</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020287">In Situ Nick-End Labeling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007306">Insecticides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007774">Lactation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007985">Leydig Cells</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008813">Mice, Inbred ICR</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009570">Nitriles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010750">Phosphoproteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011722">Pyrethrins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011863">Radioimmunoassay</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013076">Sperm Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013091">Spermatogenesis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013737">Testis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000254">growth &amp; development</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013739">Testosterone</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-4274(09)01394-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.toxlet.2009.08.007</ArticleId>
            <ArticleId IdType="pubmed">19683566</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">622433</PMID>
        <DateCreated>
            <Year>1978</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1978</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0033-3182</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>19</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1978</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Psychosomatics</Title>
                <ISOAbbreviation>Psychosomatics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lithium-induced disabling tremor.</ArticleTitle>
            <Pagination>
                <MedlinePgn>27, 31</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Van Putten</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Psychosomatics</MedlineTA>
            <NlmUniqueID>0376506</NlmUniqueID>
            <ISSNLinking>0033-3182</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>9FN79X2M3F</RegistryNumber>
                <NameOfSubstance UI="D008094">Lithium</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001714">Bipolar Disorder</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008094">Lithium</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014202">Tremor</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1978</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1978</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1978</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">622433</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19683565</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3169</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>191</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Dec</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology letters</Title>
                <ISOAbbreviation>Toxicol. Lett.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Influence of strain and sex on the metabolic profile of rats in repeated dose toxicological studies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>88-95</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxlet.2009.08.004</ELocationID>
            <Abstract>
                <AbstractText>The impact of the strain on the metabolite profile of plasma samples in rats dosed with 2500 ppm 2-methyl-4-chlorophenoxyacetic acid (MCPA acid) or 45 mg/kg bw/day 4-chloro-3-nitroaniline (4C3N) for 4 weeks was evaluated. Four different strains were used: two Wistar strains (Crl:WI(Han), Han:RCC:WIST(SPF)), one Sprague-Dawley (Crl:CD) and one Fisher strain (F-344/Crl). The metabolite profiles in the plasma were measured by LC-MS and GC-MS. The profound changes of the metabolite values induced by the MCPA acid treatment outweighed slight deviations caused by physiological variations between the different rat strains. The metabolome changes of the MCPA acid in all strains could be related to toxicological &quot;mode of action&quot; patterns (peroxisome proliferator, renal organic anionic transporter inhibition) with Crl:WI(Han) rats as reference strain. 4C3N administration led to extravascular hemolytic anemia with a small number of metabolome changes, which were strain dependent. The metabolome pattern associated with &quot;hemolytic anemia&quot; established with the reference strain (Crl:Wi(Han)) was not sufficiently similar in other strains. Thus, comparable metabolome profiles were obtained in different rat strains for a compound inducing profound metabolite changes. For a compound with a weak profile the results were more variable and appeared to be strain dependent.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Strauss</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>BASF SE Experimental Toxicology and Ecology, Z 470, 67056 Ludwigshafen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wiemer</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leibold</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kamp</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Walk</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mellert</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Looser</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prokoudine</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fabian</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krennrich</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Herold</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Ravenzwaay</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>08</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Toxicol Lett</MedlineTA>
            <NlmUniqueID>7709027</NlmUniqueID>
            <ISSNLinking>0378-4274</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006540">Herbicides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>635-22-3</RegistryNumber>
                <NameOfSubstance UI="C048360">4-chloro-3-nitroaniline</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>D888C394VO</RegistryNumber>
                <NameOfSubstance UI="D008456">2-Methyl-4-chlorophenoxyacetic Acid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008456">2-Methyl-4-chlorophenoxyacetic Acid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000743">Anemia, Hemolytic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000814">Aniline Compounds</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001711">Biotransformation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001772">Blood Cell Count</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001835">Body Weight</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004435">Eating</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006540">Herbicides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D025341">Principal Component Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011916">Rats, Inbred F344</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017207">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012727">Sex Characteristics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013045">Species Specificity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014116">Toxicology</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>12</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0378-4274(09)01389-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.toxlet.2009.08.004</ArticleId>
            <ArticleId IdType="pubmed">19683565</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16969509</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>09</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>01</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1021-335X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>16</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oncology reports</Title>
                <ISOAbbreviation>Oncol. Rep.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>877-84</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Multiple myeloma (MM) is an incurable disease with a 10-year survival of &lt;20%. We have previously shown that the combination of gemcitabine and paclitaxel acts synergistically to induce apoptosis of myeloma cells in vitro. Based on these preclinical studies and phase I-II clinical trials in patients with solid tumors, we initiated a phase II clinical trial of paclitaxel 150 mg/m(2) IV over 3 h followed by gemcitabine 3000 mg/m(2) IV over 30-60 min in patients with relapsed or refractory MM. This regimen was administered every two weeks for a total of six cycles. Twelve patients enrolled, 3 discontinued treatment after 1 or 2 cycles because of severe neutropenia. As a result the protocol was modified to reduce the starting dose of gemcitabine to 2,000 mg/m(2). This resulted in tolerable hematological and mild non-hematological toxicities in the rest of the patients. One patient died before the onset of treatment. Of the 8 remaining patients treated with a reduced dose of gemcitabine, 1 achieved a durable CR, 3 had PR, 1 had minor response (MR), 1 had stable disease and 2 had progressive disease. The CR patient had a 98% reduction in the M-protein, beta2-microglobulin and plasma cells. His CR continued for more than 6 months. The 3 PR patients had a &gt;50% reduction in the M-protein and &gt;40% reduction in beta2-microglobulin. Bone marrow plasma cells were reduced by &gt;50% in these patients. Treatment with the combination of paclitaxel and gemcitabine is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gazitt</LastName>
                    <ForeName>Yair</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX 78284, USA. gazitt@uthscsa.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shaughnessy</LastName>
                    <ForeName>Paul</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rothenberg</LastName>
                    <ForeName>Mace L</ForeName>
                    <Initials>ML</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Oncol Rep</MedlineTA>
            <NlmUniqueID>9422756</NlmUniqueID>
            <ISSNLinking>1021-335X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0W860991D6</RegistryNumber>
                <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33069-62-4</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B76N6SBZ8R</RegistryNumber>
                <NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003841">Deoxycytidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009101">Multiple Myeloma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>1</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>9</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16969509</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8496127</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>06</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>06</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0890-8567</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>32</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1993</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title>
                <ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Acute dystonic reaction with low-dose pimozide.</ArticleTitle>
            <Pagination>
                <MedlinePgn>640-2</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>It is essential to recognize individual susceptibility to neuroleptic-induced side effects for treatment guidelines. This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration. It draws the clinician's attention to unusual susceptibility to extrapyramidal side effects and suggests that if a child shows this type of susceptibility to one neuroleptic, he/she may react similarly to other neuroleptics as well.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ernst</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, New York University Medical Center, NY 10016.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonzalez</LastName>
                    <ForeName>N M</ForeName>
                    <Initials>NM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Campbell</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MH-18915</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MH-32212</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA>
            <NlmUniqueID>8704565</NlmUniqueID>
            <ISSNLinking>0890-8567</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>1HIZ4DL86F</RegistryNumber>
                <NameOfSubstance UI="D010868">Pimozide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001321">Autistic Disorder</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001480">Basal Ganglia Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010868">Pimozide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1993</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8496127</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12269398</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>10</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0024-3205</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>70</Volume>
                    <Issue>24</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>May</Month>
                        <Day>3</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Life sciences</Title>
                <ISOAbbreviation>Life Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2857-69</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Tizanidine, an alpha2-adrenergic receptor agonist with myospasmolytic action, is indicated for the treatment of back pain either as monotherapy or in combination with nonsteridal anti-inflammatory drugs (NSAIDs). Tizanidine (0.25-1.0 mg/kg) significantly produced analgesic and anti-inflammatory effect in acetic acid induced writhing in mice and carrageenan-induced paw edema in rats, respectively. The effects were comparable with clonidine (0.25 and 0.50 mg/kg), another alpha2-agonist. Yohimbine (1 mg/kg), alpha2-adrenergic antagonist reversed the effect of tizanidine. Tizanidine (0.25 mg/kg) and clonidine (0.25 mg/kg) significantly potentiated the antinociceptive and anti-inflammatory effect of NSAIDs (nimesulide, meloxicam and naproxen). Tizanidine (1 mg/kg) did not alter basal pH, acidity (free and total) of gastric content and did not produce any mucosal injury in fasted rats. Tizanidine (1 mg/kg) significantly reduced meloxicam (UD50 3.21 mg/kg), nimesulide (UD50 24.52 mg/kg) and naproxen (UD50 14.10 mg/kg)-induced ulcerogenic effect (ulcer index, pH and free/total acidity). It is expected that tizanidine exerted gastrotprotection through stimulation of gastric and central alpha2-adrenergic receptors. Present investigation suggested that tizanidine not only enhance the analgesic and anti-inflammatory effect of NSAIDs but also improved gatstrointestinal tolerability of NSAIDs through modulation of central alpha-2-receptors. From this study, it can be speculated that tizanidine and NSAID combination therapy would prove to be a novel approach to treat nociceptive/inflammatory conditions with improved gastric tolerability of NSAIDs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Naveen K</ForeName>
                    <Initials>NK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kulkarni</LastName>
                    <ForeName>Shrinivas K</ForeName>
                    <Initials>SK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Amarjit</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Life Sci</MedlineTA>
            <NlmUniqueID>0375521</NlmUniqueID>
            <ISSNLinking>0024-3205</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000316">Adrenergic alpha-Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018341">Receptors, Adrenergic, alpha-2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013843">Thiazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2Y49VWD90Q</RegistryNumber>
                <NameOfSubstance UI="D015016">Yohimbine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>51803-78-2</RegistryNumber>
                <NameOfSubstance UI="C012655">nimesulide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>57Y76R9ATQ</RegistryNumber>
                <NameOfSubstance UI="D009288">Naproxen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6AI06C00GW</RegistryNumber>
                <NameOfSubstance UI="C023754">tizanidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>71125-38-7</RegistryNumber>
                <NameOfSubstance UI="C065757">meloxicam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MN3L5RMN02</RegistryNumber>
                <NameOfSubstance UI="D003000">Clonidine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000316">Adrenergic alpha-Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003000">Clonidine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009288">Naproxen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010146">Pain</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018341">Receptors, Adrenergic, alpha-2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013276">Stomach Ulcer</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013843">Thiazines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013844">Thiazoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015016">Yohimbine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>10</Month>
                <Day>9</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12269398</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16681429</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>05</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>08</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1434-6621</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>44</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2006</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical chemistry and laboratory medicine : CCLM / FESCC</Title>
                <ISOAbbreviation>Clin. Chem. Lab. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>589-93</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Overproduction of nitric oxide (NO) and hydrogen peroxide (H(2)O(2)) may be an important factor in the pathogenesis of amyotrophic lateral sclerosis (ALS). Owing to their ability to permeate through biological membranes, excess NO and H(2)O(2) may be present in the media surrounding motor neurones. Anti-oxidative defence enzymes (ADEs) in erythrocytes are capable of detoxifying reactive oxygen species (produced endogenously or exogenously), but may also be structurally modified and inactivated by reactive oxygen and nitrogen species. Both balanced and coordinated ADE activities are of utmost importance for their correct physiological function.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We determined activity of the following ADEs: copper-zinc superoxide dismutase (CuZn SOD), catalase (CAT), glutathione peroxidase (GSH-Px) and glutathione reductase (GR) in erythrocytes from sporadic ALS patients [SALS (-/+)], familial ALS patients with the Leu144Phe mutation in the SOD1 gene [FALS (+/+)], asymptomatic carriers with the Leu144Phe mutation in the SOD1 gene (+/-), and control subjects (-/-). We also examined the in vitro effect of diethyldithiocarbamate (DDC) on CuZn SOD activity in erythrocytes from FALS patients, SALS patients and control subjects.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The influence of the Leu144Phe mutation and/or disease was apparent for ADE activities measured in all three patient groups. The SOD1 gene mutation decreased CuZn SOD and GSH-Px activity (two-way ANOVA, significant mutation effect). We noted that the disease also contributed to decreased CuZn SOD activity in SALS patients in comparison with the control group (two-way ANOVA, mutation and disease effect). The disease also influenced CAT and GR activity. CAT activity was decreased in both SALS and FALS patients. In all three patient groups, GR activity was higher than in the control group. Finally, DDC inhibited CuZn SOD activity in erythrocytes from control subjects, FALS (Leu144Phe) patients and SALS patients; however, its effect was more pronounced and significant in FALS patients.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Changes in erythrocyte ADE activities suggest that oxidative stress, involved in the motor neurone pathogenesis of SALS and FALS, also has systemic effects. Differences in ADE systems between the study groups revealed the presence of different types of oxidative pressure, indicating the potential additional benefit of individually designed anti-oxidant cocktail therapies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nikolić-Kokić</LastName>
                    <ForeName>Aleksandra</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology, Institute for Biological Research Sinisa Stanković, Bulevar Despota Stefana 142, 11060 Belgrade, Serbia and Montenegro. san@ibiss.bg.ac.yu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stević</LastName>
                    <ForeName>Zorica</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blagojević</LastName>
                    <ForeName>Dusko</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Davidović</LastName>
                    <ForeName>Biljana</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>David R</ForeName>
                    <Initials>DR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Spasić</LastName>
                    <ForeName>Mihajlo B</ForeName>
                    <Initials>MB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Clin Chem Lab Med</MedlineTA>
            <NlmUniqueID>9806306</NlmUniqueID>
            <ISSNLinking>1434-6621</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.6</RegistryNumber>
                <NameOfSubstance UI="D002374">Catalase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.11.1.9</RegistryNumber>
                <NameOfSubstance UI="D005979">Glutathione Peroxidase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.15.1.1</RegistryNumber>
                <NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.8.1.7</RegistryNumber>
                <NameOfSubstance UI="D005980">Glutathione Reductase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000690">Amyotrophic Lateral Sclerosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002374">Catalase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004912">Erythrocytes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005979">Glutathione Peroxidase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005980">Glutathione Reductase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013482">Superoxide Dismutase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>8</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>5</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1515/CCLM.2006.111</ArticleId>
            <ArticleId IdType="pubmed">16681429</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1291253</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>03</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>03</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0412-4057</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>25</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1992</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry</Title>
                <ISOAbbreviation>Zhonghua Shen Jing Jing Shen Ke Za Zhi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Predicting the effects of haloperidol on schizophrenics by quantitative pharmaco-EEG].</ArticleTitle>
            <Pagination>
                <MedlinePgn>300-2, 318</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In order to predict the short-term-outcome of schizophrenics under the treatment of haloperidol, changes of 15 schizophrenic subjects' EEG after 4 mg haloperidol oral intake were monitored with the method of QPEEG. The result of discriminate analysis showed that the more similar to typical EEG pattern of neuroleptics the patients showed, the better the patients responded to haloperidol treatment. Meanwhile, the haloperidol therapeutic mechanisms of brain electro-physiology and the electro-physiological characteristics of schizophrenics were also discussed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>X L</ForeName>
                    <Initials>XL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Mental Health, Beijing Medical University.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>CHINA</Country>
            <MedlineTA>Zhonghua Shen Jing Jing Shen Ke Za Zhi</MedlineTA>
            <NlmUniqueID>16210510R</NlmUniqueID>
            <ISSNLinking>0412-4057</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>J6292F8L3D</RegistryNumber>
                <NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006220">Haloperidol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011379">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>10</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1291253</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12730697</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>07</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>02</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1061-4036</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>34</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>154-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Abifadel</LastName>
                    <ForeName>Marianne</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>INSERM U383, Hôpital Necker-Enfants Malades, AP-HP, Université Paris V, 149-161 rue de Sèvres, 75743 Paris Cedex 15, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varret</LastName>
                    <ForeName>Mathilde</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rabès</LastName>
                    <ForeName>Jean-Pierre</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allard</LastName>
                    <ForeName>Delphine</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ouguerram</LastName>
                    <ForeName>Khadija</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Devillers</LastName>
                    <ForeName>Martine</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cruaud</LastName>
                    <ForeName>Corinne</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Benjannet</LastName>
                    <ForeName>Suzanne</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wickham</LastName>
                    <ForeName>Louise</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Erlich</LastName>
                    <ForeName>Danièle</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Derré</LastName>
                    <ForeName>Aurélie</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Villéger</LastName>
                    <ForeName>Ludovic</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farnier</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beucler</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bruckert</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chambaz</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chanu</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lecerf</LastName>
                    <ForeName>Jean-Michel</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luc</LastName>
                    <ForeName>Gerald</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moulin</LastName>
                    <ForeName>Philippe</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Weissenbach</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prat</LastName>
                    <ForeName>Annick</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krempf</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Junien</LastName>
                    <ForeName>Claudine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Seidah</LastName>
                    <ForeName>Nabil G</ForeName>
                    <Initials>NG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boileau</LastName>
                    <ForeName>Catherine</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>OMIM</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>144400</AccessionNumber>
                        <AccessionNumber>176000</AccessionNumber>
                        <AccessionNumber>603776</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 3.4.-</RegistryNumber>
                <NameOfSubstance UI="D043484">Proprotein Convertases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.21.-</RegistryNumber>
                <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.21.-</RegistryNumber>
                <NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Circ Cardiovasc Genet. 2014 Dec;7(6):967-8</RefSource>
                <PMID Version="1">25516627</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019943">Amino Acid Substitution</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002878">Chromosomes, Human, Pair 1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005799">Genes, Dominant</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008040">Genetic Linkage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006938">Hyperlipoproteinemia Type II</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008099">Liver</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010375">Pedigree</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043484">Proprotein Convertases</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012697">Serine Endopeptidases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>6</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>7</Month>
                <Day>4</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2003</Year>
                <Month>Feb</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2003</Year>
                <Month>Mar</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>5</Month>
                <Day>6</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12730697</ArticleId>
            <ArticleId IdType="doi">10.1038/ng1161</ArticleId>
            <ArticleId IdType="pii">ng1161</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
